Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals



Date: 4<sup>th</sup> September, 2023 The Manager BSE Limited 25th Floor, Phiroze Jeejabhoy Towers, Dalal Street Mumbai- 400001

SCRIP CODE: 540359

Sub.: Submission of Annual Report for the Financial Year 2022-23.

Dear Sirs,

Pursuant to the provisions of Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Annual Report of the Company for the Financial Year 2022-23. Kindly take the same on records.

Thanking you,

Yours Faithfully,

For Parmax Pharma Limited

YASH JAYESHBHAI VORA

Digitally signed by YASH JAYESHBHAI VORA Date: 2023.09.04 14:17:07 +05'30'

Yash Vora

**Company Secretary** 

Encl.: As above



# **ANNUAL REPORT 2022-23**

# **Contents:**

Corporate Information	2
Directors' Report & Management Discussion and Analysis	3
Report on Corporate Governance	20
Auditors' Report	33
Statement of Assets and Liabilities	44
Statement of Profit and Loss	46
Cash Flow Statement	48
Notes to the Financial Statements	49
Key Financial Ratios	64

# Parmax Pharma Limited

# Corporate Information

Board of Directors:

Dr. Umang A. Gosalia - Managing Director

Mr. Pramay A. Chhatra - Independent Director (till 25.04.2023)

Mr. Nikhil S. Uchat - Independent Director (with effect from 25.04.2023)

Ms. Ami R. Shah - Independent Director

Key Managerial Personnel:

Mr. Yash J. Vora (CS and Compliance Officer)
Mr. Keyur D. Vora (Chief Financial Officer)

Statutory Auditors: M/s B A Shah S R Mehta & Co., Chartered Accountants Rajkot Secretarial Auditors: Mr. Samsad Alam Khan Company Secretaries Ahmedabad

#### **Bankers:**

- HDFC Bank
- ICICI Bank

Registered Office & Works: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani,

Rajkot - 360311, Gujarat

Contact Number: 02827 - 270 534 / 270

Email: - <u>info@parmaxpharma.com</u>
Website: - <u>www.parmaxpharma.com</u>

Registrar and Transfer Agent:
Purva Sharegistry (India) Pvt.
Ltd.,Unit no. 9, Shiv Shakti
Ind. Estate,
J. R. Boricha Marg, Opp. Kasturba
Hospital Lane, Lower Parel (E), Mumbai - 400 011

Corporate Identification Number: L24231GJ1994PLC023504

# DIRECTORS' REPORT & MANAGEMENT DISCUSSION AND ANALYSIS

# Dear Shareholders,

The Board of Directors are pleased to present their 29<sup>th</sup> Annual Report on the business and operations of the Company and the Audited financial accounts for the Year ended 31<sup>st</sup> March, 2023.

# **Financial Results:**

(Rs. In lacs.)

Particulars	For the year ended on 31 <sup>st</sup> March, 2023	For the year ended on 31 <sup>st</sup> March, 2022
Net Total Income	1546.41	1831.39
Less: Operating and Admin. Exps.	1353.94	1607.85
Profit before depreciation and Taxes	192.47	223.54
Less: Depreciation	187.86	193.21
Less: Extraordinary/Exceptional Items	0	0
Net Profit/(Loss) on sale of Fixed Assets	0	0
Profit before Tax (PBT)	4.61	30.33
Less: Taxes (including deferred tax and fringe benefit tax)		
Profit after Tax (PAT)	-10.40	14.32
Balance Available for appropriation	140.48	150.88
Which the Directors propose to appropriate as under:		
(i) Proposed Dividend	0	0
(ii) Corporate Dividend Tax	0	0
Surplus Carried to Balance Sheet	-10.40	14.32
Earnings Per Equity Share		
Basic	-0.28	0.38
Diluted	-0.28	0.38

<sup>\*-</sup> Amount of EPS is in Rs.

# **HIGHLIGHTS OF PERFORMANCE:**

# • Revenue from Operations

In FY 2023, your Company recorded total revenue from operations of Rs. 1542.43 lacs as against Rs. 1825.11 lacs in FY 2022. Due to poor market conditions and other several factors the Company witnessed the 15% decline in the revenue.

# • Reported Net Profit after Tax / (Loss)

In FY 2023, your Company recorded negative profit / (Loss) of Rs. 10.40 lacs against the Profit after tax of Rs. 14.32 lacs in previous year. .

# **DIVIDEND:**

Keeping in view the financial results and in order to conserve financial resources for the future requirement of the fund, your directors do not recommend any dividend during the year under review

#### **PUBLIC DEPOSITS:**

The Company had accepted deposits of Rs. 25 Lakh from Relative of Directors and Promoters and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act

and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the relative of Director contravenes.

# SUBSIDIARY/ JOINT VENTURE/ ASSOCIATE COMPANY:

As on 31<sup>st</sup> March, 2023, Your Company has *Nil* Subsidiary/Joint Venture/ Associate Company.

#### **TRANSFER TO RESERVES:**

During the year under review, no amount was transferred to general reserves by the Company.

### **INTERNAL CONTROL SYSTEMS:**

Your Company has a robust system of internal controls commensurate with the size of the Company and the nature of its business, which ensures that transactions are recorded, authorised and reported correctly apart from safeguarding itsassets against loss from wastage, unauthorized use and disposition. The internal control systems are supplemented by well documented policies, guidelines and procedures which are in line with the internal financial control framework requirements. There is an extensive programme of internal audit by a firm of chartered accountants followed by periodic management reviews. The Audit Committee actively reviews the adequacy and effectiveness of the internal control systems and suggests improvements to strengthen the same.

#### **RISK MANAGEMENT:**

Your Company considers that risk is an integral part of its business and therefore, it takes proper steps to manage all risks in a proactive and efficient manner. The Company management periodically assesses risks in the internal and external environment and incorporates suitable risk treatment processes in its strategy and business and operating plans. The details of practices being followed by the Company in this regard, form part of the Corporate Governance Report. There areno risks which, in the opinion of the Board, threaten the very existence of your Company. However, some of the challenges faced by it have been dealt with under Management Discussion and Analysis which forms part of this Report.

# **BOARD MEETINGS HELD DURING THE YEAR:**

Details of the meetings of the Board held during the year, form part of the Corporate Governance Report

# **DIRECTORS AND KEY MANAGERIAL PERSONNEL:**

- In terms of Section 152 of the Companies Act, 2013, Mr. Umang Alkesh Gosalia (DIN: 005173830) is liable to retire by rotation at forthcoming AGM and being eligible offers himself for re-appointment.
- A brief resume of director being re-appointed with the nature of their expertise, their shareholding in the Company as stipulated under as required under Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed to this Notice of the ensuing Annual General Meeting.
- The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013, that he/she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 16(1) (b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- All the directors of the Company have confirmed that they are not disqualified from being appointed as directors in terms of Section 164 of the Companies Act, 2013.

# MATTERS AS PRESCRIBED UNDER SUB-SECTIONS (1) AND (3) OF SECTION 178 OF THE COMPANIES ACT 2013:

The policy of the Company on directors' appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of a director and other matters provided under Sub section (3) of Section 178 of the Companies Act, 2013, adopted by the Committee, is appended in the Corporate Governance Report.

#### **DIRECTORS' RESPONSIBILITY STATEMENT**

Pursuant to the requirement under Section 134(3)(c) of the Companies Act, 2013 (the 'Act'), the Directors, to the best of their knowledge, confirm that:

- i. In the preparation of the Annual Accounts, the applicable Accounting Standards have been followed along with proper explanation relating to material departures, if any;
- ii. Appropriate accounting policies have been applied consistently and judgements and estimates that are reasonable and prudent have been made so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for the period;
- iii. Proper and sufficient care has been taken for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv. The Annual Accounts have been prepared on a going concern basis;
- v. The internal financial controls to be followed by the Company have been laid down and such internal financial controls are adequate and are operating effectively; and
- vi. Proper systems have been devised to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

#### EXTRACT OF ANNUAL RETURN AS PER SECTION 92 (3) OF COMPANIES ACT, 2013:

The Annual Return as required under Section 92 and Section 134 of the Companies Act, 2013 read with Rule 12 of the Companies (Management and Administration) Rules, 2014 is available on the website of the Companyand the web-link for the same is https://www.parmaxpharma.com/investor\_relations.php

#### **KEY FINANCIAL RATIOS:**

Key Financial Ratios for the financial year 2022-23 with comparatives for the year 2021-22, are disclosed in Financial Statements.

Management has also provided the reasons for where variances are in excess of 25% compared to previous year and Management is very proactive and is actively evaluating the causes of differences in ratios and actively working for improving its ratios.

### **BOARD EVALUATION:**

Pursuant to the provisions of the Companies Act, 2013, the Board has carried out an annual evaluation of its own performance, the directors individually, as well as the evaluation of the working of its Committees. At the meeting of the Board all the relevant factors that are material for evaluating the performance of individual Directors, the Board and its various committees were discussed in detail. A

structured questionnaire each for evaluation of the Board, its various Committees and individual Directors was prepared and recommended to the Board by Nomination & Remuneration Committee for doing the required evaluation after taking into consideration the input received from the Directors covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, execution and performance of specific duties, obligations and governance etc.

#### **AUDITORS:**

#### STATUTORY AUDITORS:

In terms of provisions of Section 139 of the Act and the Rules made thereunder, the Shareholders of the Company have appointed M/s B.A. Shah S.R. Mehta & Co., Chartered Accountants for the purpose of carrying out Statutory Audit of the Company.

The existing term of office of M/s. B A Shah S R Mehta & Co., Chartered · Accountants, Statutory Auditors is valid upto the ensuing Annual General Meeting of the Company.

The Board of Directors of the Company at their meeting held on 14.08.2023 has approved the reappointment of M/s. B A Shah S R Mehta & Co., as the statutory Auditors for a second term of 5 (Five) years commencing from the conclusion of ensuing i.e. 29th Annual General Meeting till the conclusion of the 34th Annual General Meeting to be held in the year 2028, subject to the approval of Shareholders in ensuing AGM.

The Independent Auditors Report for FY 2023 has been obtained and contains one qualification for which requires comments from the Board.

# Reporting of Frauds by Auditors

During the year, there were no instances of frauds reported by Auditors under Section 143(12) of the Act.

# SECRETARIAL AUDITOR

The Board has appointed Mr. Samsad Alam Khan, Company Secretaries to conduct Secretarial Audit in accordance with the provisions of Section 204 of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 for FY 2023. The Secretarial Audit Report for FY 2023 has been obtained and contains one qualification for which requires any comments from the Board. The Secretarial Audit Report for FY 2023 is annexed to this report as Annexure -B.

# COST AUDIT

The provisions of Cost Audit are not applicable on the Company.

#### BOARD RESPONSE TO SECRETARIAL AUDIT REPORT AND AUDIT REPORT:-

Your Board of Directors would like to clarify the qualification remarks made in Secretarial Audit Report asunder:-

#### **BOARD RESPONSE TO SECRETARIAL AUDIT:-**

Qualification/ Adverse Remark	Explanation :
Company has not complied with the provisions of Section 74 of the Companies Act, 2013 regarding acceptance of deposits.	The Board is in process of complying with Section 74 of Companies Act, 2013 regarding Acceptance of deposits.  However, Board assures to comply with the Act and Regulations.

#### **BOARD RESPONSE TO STATUTORY AUDIT REPORT:-**

Qualification/ Adverse Remark	Explanation :
The Company has accepted deposits of Rs. 25 Lakh from Relative of Directors and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the relative of Director is contravening.	The Board is in process of complying with Section 74 of Companies Act, 2013 regarding Acceptance of deposits.

#### **INTERNAL AUDITORS:**

The Board appointed M/s. B A Shah & Associates., Chartered Accountants (Firm Registration Number:-109493W) hereby appointed as Internal Auditor of the company for the financial year 2022-23. The report prepared by the Internal Auditors is to be reviewed by the Statutory Auditors & Audit Committee.

# PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186:

Details of Loans, Guarantees and Investments under the provisions of Section 186 of the Companies Act,2013 are not applicable to the Company.

# **AUDIT COMMITTEE:**

The composition and the functions of the Audit Committee of the Board of Directors of the Company is disclosed in the Report on Corporate Governance, which is forming a part of this report.

# **RELATED PARTY TRANSACTIONS:**

All the related party transactions entered into during the financial year were on an arm's length basis and were in the ordinary course of business. Accordingly, the disclosure of related party transactions as required under Section 134(3) (h) of the Companies Act, 2013 in Form AOC 2 is attached in "Annexure C".

#### SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

During the year under review, no significant and material order was passed by the Regulators/Courts that could impact the going concern status of the Company and its future operations.

There is no proceeding pending under the Insolvency and Bankruptcy Code, 2016. There was no instanceof onetime settlement with any Bank or Financial Institution.

# POLICY AGAINST SEXUAL HARASSMENT AT WORKPLACE

The Company values the dignity of individuals and is committed to provide an environment, which is free of discrimination, intimidation and abuse. The Company has put in place a policy on redressal of Sexual Harassment and a Policy on redressal of Workplace Harassment as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ("Sexual Harassment Act"). As per the policy, any employee may report his/ her complaint to the Redressal Committee formed for this purpose or their Manager or HR personnel. The company has also constituted an Internal Complaints Committee to inquire into complaints of sexual harassment and recommendation for appropriate action. No complaints have been filed/ disposed of/ pending during the financial year ended 31st March, 2023.

#### **MATERIAL CHANGES:**

There are no material changes and commitments, that would affect financial position of the company from the end of the financial year of the company to which the financial statements relate and the date of the directors report.

# CONSERVATION OF ENERGY, RESEARCH AND DEVELOPMENT, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The particulars prescribed under Section 134(3)(m) of the Companies Act, 2013, read with Rule 8(3) of the Companies (Accounts) Rules, 2014 are attached as 'Annexure - D'

# **CORPORATE GOVERNANCE:**

The Company is committed to maximize the value for its stakeholders by adopting the principles of good Corporate Governance in line with the provisions of law and particularly those stipulated in the Listing Regulations. Its objective and that of its management and employees is to manufacture and market the Company's products in a way so as to create value that can be sustained over the long term for consumers, shareholders, employees, business partners and the national economy in general.

Certificate from the Practicing Company Secretary regarding compliance of the conditions of Corporate Governance as stipulated in the Listing Regulations, is enclosed.

#### **RISK MANAGEMENT:**

Your Company considers that risk is an integral part of its business and therefore, it takes proper steps to manage all risks in a proactive and efficient manner. The Company management periodically assesses risks in the internal and external environment and incorporates suitable risk treatment processes in its strategy and business and operating plans.

There are no risks which, in the opinion of the Board, threaten the very existence of your Company. However, some of the challenges faced by it have been dealt with under Management Discussion and Analysis which forms part of this Report.

Details regarding constitution of Risk Management Committee, its role and responsibilities, form part of the Corporate Governance Report.

The details of practices being followed by the Company in this regard form part of the Corporate Governance Report.

#### **CORPORATE SOCIAL RESPONSIBILITY:**

This clause is not applicable.

#### **KEY MANAGERIAL PERSONNEL:**

As at end of the year, Dr. Umang Gosalia, Managing Director, Mr. Keyur D Vora, Chief Financial Officer and CS Yash Vora, Company Secretary were the Key Managerial Personnel of the Company.

# **VIGIL MECHANISM/WHISTLE BLOWER POLICY:**

Your Company is committed to highest standards of ethical, moral and legal business conduct. Accordingly, the Board of Directors have formulated a Whistle Blower Policy which is in compliance with the provisions of Section 177(10) of the Companies Act, 2013 and Regulation 22 of the SEBI (LODR), Regulations, 2015. It is framed for employees and Directors of the company to report to the management instances of unethical behavior, actual or suspected fraud or violation of the company's code of conduct. This policy enables the employees or directors of Company to approach the Chairman of Audit Committee.

Further, the whistle blower policy is available at the website of our company a http://www.parmaxpharma.com/policies.php

#### **DECLARATION OF INDEPENDENT DIRECTORS:**

All Independent Directors have given declaration that they meet the criteria of independence as provided under Section 149 of the Act and Regulation 16 of the Listing Regulations.

The Independent Directors have also complied with the Code for Independent Directors as per Schedule IV of the Act. All our Independent Directors are registered on the Independent Directors Databank. None of the Directors of the Company are disqualified for being appointed as Directors as specified under Section 164(2) of the Act read with Rule 14(1) of the Companies (Appointment and Qualification of Directors) Rules, 2014.

# THE CHANGE IN NATURE OF BUSINESS:

There is no material change in the business of the Company during the year under review.

#### MATERIAL CHANGES IN FINANCIAL POSITION:

No material change or commitment has occurred after the close of FY 2023 till the date of this Report, which affects the financial position of the Company

#### **PARTICULARS OF EMPLOYEES:**

A statement containing the names and other particulars of employees in accordance with the provisions of section 197(12) of the Companies Act, 2013 read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as "Annexure – C" to this report.

No employee has received remuneration in excess of the limits set out in rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 during FY 2022-23.

# **ORDERS PASSED BY COURTS/ REGULATORS:**

No significant or material order has been passed by the regulators or courts or tribunals impacting the going concern status of the Company or its future operations.

#### **ACKNOWLEDGMENT:**

The Directors wish to place on record their appreciation to the devoted services of the workers, staff and the officers who largely contributed to the efficient management of the Company in the difficult times. The Directors place on record their appreciation for the continued support of the shareholders of the Company. The Directors also take this opportunity to express their grateful appreciation for assistance and cooperation received from the bankers, vendors and stakeholders including financial institutions, Central and State Government authorities, other business associates, who have extended their valuable sustained support and encouragement during the year under review.

By and order of Board of Directors For, Parmax Pharma Limited

Date: 14th August, 2023

Place: Rajkot

Dr. Umang Gosalia Managing Director DIN: 05153830

# Annexure-A

# FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. Details of contracts or arrangements or transactions at arm's length basis:

SI	Names of related party and Nature of relationship	Nature of contracts/ arrangem ents / transactions	Duration of contracts/arrangements / transactions	Salient terms of the contracts/ arrangements /transactions	Justification for entering into such contracts or arrangements	Dates of approv alby the Board	Amount paid as advance, if any	Date of special resolution u/s 188
	NA			N.A.	N.A.			N.A.

2. Details of contracts or arrangements or transactions not at arm's length basis:

S	Names of related party and Nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of contracts/ arrangements/ transactions	Salient terms of the contracts/ arrangements/ transactions	Justification for entering into such contracts or arrangements	Dates of approval by the Board	Amount paid as advances, if any	Date of special resolution u/s 188
1	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

By and order of Board of Directors for, Parmax Pharma Limited

Date: 14th August, 2023

Place: Rajkot

Dr. Umang Gosalia Managing Director DIN: 05153830

Annexure-B

# Form No. MR-3 SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31st March, 2023

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members,
Parmax Pharma Limited
Plot No. 20, Survey No. 52,
Rajkot-Gondal National Highway No. 27,
Hadamtala, Rajkot-360311

I, Samsad Alam Khan, Company Secretaries, have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Parmax Pharma Limited [CIN: L24231GJ1994PLC023504]** hereinafter called the Company. Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of Parmax Pharma Limited's books, papers, minute books, forms and returnsfiled and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2023 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by Parmax Pharma Limited for the financial year ended on 31st March, 2023 according to the provisions of:

- I. The Companies Act, 2013 ('the Act') and the rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- III. The Depositories Act, 1996 and the Regulations and Byelaws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings. (Not applicable to the company during the Audit period)
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India

c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (Not Applicable to the Company during the Audit Period);

- d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; (Not Applicable to the Company during the Audit Period);
- e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 (Not Applicable to the Company during the Audit period);
- f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client (Not Applicable as the Company is not registered as Registrar and Transfer Agents with SEBI);
- g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Not Applicable to the Company during the Audit Period) and;
- h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 (Not Applicable to the Company during the Audit Period).
- I. As informed to me the following other Laws specifically applicable to the Company as under:

#### A. INDUSTRIAL & LABOUR LAWS AND ENVIORNMENT RELATED:

- a) The Environment (Protection) Act, 1986
- b) The Factories Act, 1948
- c) The Minimum Wages Act, 1948
- d) The Payment of Wages Act, 1936
- e) Employee's State Insurance Act, 1948
- f) Employees' Provident Fund and Miscellaneous Provisions Act, 1952
- g) The Payment of Bonus Act, 1965
- h) The Payment of Gratuity Act, 1972
- i) The Contract Labour (Regulation and Abolition) Act, 1970
- j) The Maternity Benefit Act, 1961
- k) The Child Labour (Prohibition and Regulation) Act, 1986
- 1) The Industrial Employment (Standing Orders) Act, 1946
- m) The Apprentices Act, 1961

I have also examined compliance with the applicable clauses of the following:

- a) Secretarial Standards with respect to General and Board Meetings Minutes issued by TheInstitute of Company Secretaries of India (effective from 1st July, 2015).
- b) The Listing Agreements entered into by the Company with BSE Limited.
- c) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. (effective from 1st December, 2015)

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above except to the extent as mentioned below.

i. Company has not complied with the provisions of Section 74 of the Companies Act, 2013 regarding continuation of deposits.

# I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. There is no Change in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors, to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions of the board were unanimous and the same was captured and recorded as part of the minutes.

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period there were no specific events / actions having a major bearing on the Company's affairs.

Place: Ahmedabad Date: 14.08.2023

Samsad Alam Khan Company Secretaries CP No: 13972

UDIN: A028719E000800116

**Note:** This Report is to be read with Our Letter of even date which is annexed as "Appendix A" and forms an integral part of this report.

'Appendix A'

To,
The Members,
Parmax Pharma Limited
Plot No. 20, Survey No. 52,
Rajkot-Gondal National Highway No. 27,
Hadamtala, Rajkot-360311

Our Secretarial Audit Report of even date is to be read along with this letter.

- 1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
- 2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
- 3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
- 4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
- 5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
- 6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

Place: Ahmedabad Date: 14.08.2023

Samsad Alam Khan Company Secretaries

CP No: 13972

UDIN: A028719E000800116

# **ANNEXURE - C TO DIRECTORS' REPORT**

# **PARTICULARS OF EMPLOYEES:-**

(Pursuant to rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014.

- 1. There increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2022-23, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2022-23.
- **2.** The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year;

Sr. No.	Name of Director/KMP	Remuneration for FY 2022-23 (in Rs)	remuneration in FY 2022-23	Ratio of remuneration of director to median remuneration of employees.
1.	Mr. Umang A Gosalia Managing Director	Rs. 39,00,000/-	Nil	9.64x
2.	Mr. Pramay A Chhatra Independent Director	Nil	Nil	NA
3.	Ms. Ami Shah Independent Director	Nil	Nil	NA
4.	Mr. Keyur D Vora Chief Financial Officer	Rs.13,88,640/-	Nil	3.43x
5.	CS Yash Vora Company Secretary	Rs. 5,85,420/-	Nil	1.44x

- 3. No sitting fees and commission paid to Independent Directors during the year under review
- **4.** The number of employees on the rolls of the company as on March 31, 2023 is 94.
- **5.** The remuneration stated above is in accordance with the remuneration policy of the company.
- **6.** During the Financial year No employee has received per annum remuneration exceeding Rs. 1.02 Crore or Rs. 8.50 Lacs per month.

# Annexure - D

# CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

Conservation of Energy:

The Company is committed in conserving energy in its various operational activities. Energy efficiency improvement, waste heat recovery, process optimisation and alternate renewable energy sources are the major focus area identified for energy conservation. There is a dedicated energy conservation team, consistently working with structured approach to reduce energy consumption.

The Company continues its policy of giving priority to energy conservation measures including regular review of energy conservation, consumption and effective control of utilization of energy.

Steps taken or impact on conservation of energy:

- Replacement of old motors with the efficient motors in Plants
- Improving the efficiency of air compressors .

The company is also considering the alternate sources of energy for conservation of energy.

# FOREIGN EXCHANGE EARNINGS AND OUTGO

Foreign Exchange inflow (Rs.): NIL Foreign Exchange outflow (Rs.): NIL

# MANAGEMENT DISCUSSION AND ANALYSIS

# Global Economy:

On the surface, the global economy appears poised for a gradual recovery from the powerful blows of the pandemic and Russia's unprovoked war on Ukraine. Supply-chain disruptions are unwinding, while the dislocations to energy and food markets caused by the war are receding. Simultaneously, the massive and synchronous tightening of monetary policy by most central banks should start to bear fruit as inflation starts tapering off.

The baseline forecast is for growth to fall from 3.4% in 2022 to 2.8% in 2023, before settling at 3.0% in 2024. Advanced economies are expected to see an especially pronounced growth slowdown, from 2.7% in 2022 to 1.3% in 2023. Global headline inflation in the baseline is set to fall from 8.7% in 2022 to 7.0% in 2023 on the back of lower commodity prices but underlying (core) inflation is likely to decline more slowly.

The rate hike by the US Fed drove capital into the US markets causing the US Dollar to appreciate against most currencies. This led to the widening of the Current Account Deficits (CAD) and increased inflationary pressures in net importing economies. The rate hike and persistent inflation also led to a lowering of the global growth forecasts for 2022 and 2023. The weakness of the Chinese economy further contributed to weakening the growth forecasts. With inflation persisting in the advanced economies and the central banks hinting at further rate hikes, downside risks to the global economic outlook appear elevated.

# Indian Economy:

Indian economy, however, appears to have moved on after its encounter with the pandemic, staging a full recovery in 2021-22 ahead of many nations and positioning itself to ascend to the pre-pandemic growth path in 2022-23. Yet in the bygone fiscal year, India has also faced the challenge of reining in inflation that the European strife accentuated. Measures taken by the government and RBI, along with the easing of global commodity prices, have finally managed to bring some relief on retail inflation. However, the challenge of the depreciating rupee, although better performing than most other currencies, persists with the likelihood of further increases in policy rates by the US Fed. The widening of the CAD may also continue as global commodity prices remain elevated and the growth momentum of the Indian economy remains strong. The loss of export stimulus is further possible as the slowing world growth and trade shrinks the global market size.

Despite these, agencies worldwide continue to project India as the fastest-growing major economy at 6.5-7.0% in 2022-23. These optimistic growth forecasts stem in part from the resilience of the Indian economy seen in the rebound of private consumption seamlessly replacing the export stimuli as the leading driver of growth. The uptick in private consumption has also given a boost to production activity resulting in an increase in capacity utilization across sectors. The rebound in consumption was engineered by the near-universal vaccination coverage overseen by the government. The Capital Expenditure (Capex) of the central government, which increased by 63.4% in the first eight months of 2022-23, was another growth driver of the Indian economy.

Global growth has been projected to decline in 2023 and is expected to remain generally subdued in the following years as well. The slowing demand will likely push down global commodity prices and improve India's CAD. India's economic growth in 2022-23 has been principally led by private consumption and capital formation. However, CAD needs to be closely monitored as the growth momentum of the current year spills over into the

next. Growth is expected to be brisk in 2023-24 as a vigorous credit disbursal, and capital investment cycle is expected to unfold in India with the strengthening of the balance sheets of the corporate and banking sectors.

FY 2024 continues to hint at continuing challenges since the volatility in raw material and energy prices persists. Although energy prices have shown signs of softening in the last quarter of FY 2023, we anticipate this trend to continue throughout FY 2024.

Amidst these challenges, we remain steadfast in our commitment to sustainability and compliance. Our focus on these aspects will continue while ensuring timely and complete supplies.

# The Way Forward

We are dedicated to embracing change, seizing opportunities and fostering a culture of innovation that propels us forward as a global leader in our industry. So, even as we navigate these unprecedented times, we recognize that the challenges we face are not to be feared.

# CORPORATE GOVERNANCE REPORT For the year ended 31<sup>st</sup> March, 2023

#### 1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

The Company has always been committed to the principles of good corporate governance which inter alia includes protection of shareholders rights, enhancement of shareholder value, equitable treatment of all shareholders, stakeholders such as suppliers, customers and employees and to report financial information adequately and transparently. A continuous process of delegation of powers commensurate to accountability, coupled with trust, faith and transparency has been embedded in the day to day functioning. A system to effectively manage risks has been implemented. The Company has been disclosing detailed information on different issues concerned the Company's performance from time to time.

This report sets out the compliance status of the Company with the requirements of corporate governance, as set out in Pursuant to Regulation 34(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year 2022-23.

# 2. Board of Directors:

# i. Composition of the Board

The Board consists of an optimal combination of Executive and Non-Executive Directors, including Independent Non-Executive Directors and a Women Independent Director, representing a judicious mix of business acumen, professionalism, knowledge and experience.

The Directors bring in expertise in the fields of strategy, management and finance. They provide leadership, strategic guidance, objective and independent views to the Company's management while discharging their fiduciary responsibilities, thereby ensuring that the management adheres to highest standards of ethics, transparency and compliance.

As on 31st March, 2023, the Board comprised two Independent Directors (including a woman director) and One Executive Director. The independent directors of the Company have already submitted their declarations affirming their status as independent directors as on March 31, 2023.

Composition of Board of Directors as on 31st March, 2023 is as under:-

Umang A. Gosalia - Executive

Pramay A. Chhatra – Non Executive and Independent

Ami R. Shah - Non Executive and Independent

ii. Attendance of each director at the meeting of the board of directors and the last annual general meeting;

During the financial year 2022-2023, the Board of Directors of your Company met 4 (Four) times on 30.05.2022,12.08.2022, 12.11.2022, and 14.02.2023.

The details of directors and their attendance at the board meetings and Last Annual General Meeting of the Company are as under:-

Name of Directors	No. of Board Meeting attended	Attendance at last AGM held on 30 <sup>th</sup>
		September, 2022
Umang A. Gosalia	4	Yes
Pramay A. Chhatra	4	Yes
Ami R. Shah	4	Yes

# iii. Number of other board of directors or committees in which a directors is a member.

Name of the Director	Category	Total No. of Other Directorship (In Public & Listed Companies)	Details of Commit Companies (In Pub Companies)	
			Chairman	Member
Umang A. Gosalia	Executive	Nil	Nil	Nil
Pramay A. Chhatra	Independent	Nil	Nil	Nil
Ami R. Shah	Independent	Nil	Nil	Nil
Nikhil Uchat	Independent	Nil	Nil	Nil

# Key qualifications, expertise and attributes

The following are the skills/expertise/competencies that are required in the context of the company's business(es) and sector(s) and the directors who possess such skills/expertise/competencies:

Sr. No.	Name of the Director	Skills/Expertise/Competencies	
1.	Umang A. Gosalia	Leadership and Entrepreneurship skills, Expertise in Manufacturing, Research & Development	
2.	Pramay A. Chhatra	Expertise in Import Export & Public Relations skills	
3.	Ami R. Shah	Expertise in Information technology & Public Relations skills	
4.	Nikhil Uchat	Expertise in Financial & Administrative	

All information mentioned in Part A of Schedule II to Regulation 17 (7) of SEBI LODR Regulation 2015, was made available to the Board in addition to the regular business items.

# Relationships between directors inter-se; Not Applicable

# **Resignation of Independent Directors:**

No independent Director of the Company has resigned from the Company during the year under report, however Mr. Pramay Chhatra – Independent Director has resigned from the post of Independent Director on account of his proccupation and personal reasons with effect from 25<sup>th</sup> April, 2023, he has also confirmed that there is no any other reason for his resignation.

Based on recommendation of Nomination Remuneration Committee Board has appointed Mr. Nikhil Uchat as an independent Director with effective from 25<sup>th</sup> April, 2023 simultaneously approval of shareholders has been obtained on 20<sup>th</sup> July, 2023 via special resolution through postal ballot.

#### 3. AUDIT COMMITTEE

The Audit Committee, comprising Three Directors, out of them majority members are of Non-Executive and Independent Directors and all of them have financial and accounting knowledge. The constitution of Audit Committee also meets with the requirements under Section 177 of the Companies Act, 2013 and as per Regulation 18 of SEBI (LODR) Reg, 2015. Members are regularly present at the meetings.

a. The Composition of an Audit Committee as on 31.03.2023 and details of committee meetings attended by members are as under:-

Mr. Pramay A. Chhatra – Chairman

Mr. Umang A. Gosalia – Member

Ms. Ami Shah - Member

Audit Committee has met 4 (Four) times on 30.05.2022,12.08.2022, 12.11.2022, and 14.02.2023.

Name of Members	Total Meetings held during the year	No. of meetings attended
Mr. Pramay A. Chhatra	4	4
Ms. Ami Shah	4	4
Mr. Umang A. Gosalia	4	4

Mr. Pramay A. Chhatra being a Chairman of Audit Committee has attended the Annual General Meeting of the Company held on 30th September, 2022.

- b. Keeping in view the provisions of section 177 of the Act, and the provisions of the SEBI (LODR) Regulations, 2015, the terms of reference of the Audit Committee include the following:-
- I. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- II. Recommending the appointment, remuneration and terms of appointment of statutory auditors, including cost auditors of the Company;
- III. Approving payment to statutory auditors, including cost auditors, for any other services rendered by them;
- IV. Reviewing with management the quarterly and annual financial statements before submission to the board, focusing primarily on;
  - Matters required to be included in the Directors' Responsibility Statement to be included in the Board's Report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013;
  - > Changes, if any, in accounting policies and practices and reasons for the same;
  - Major accounting entries involving estimates based on the exercise of judgement by the management;
  - > Compliance with listing and other legal requirements relating to financial statements;
  - > Disclosure of any related party transactions; and
- V. Reviewing with the management, performance of statutory and internal auditors, external and Cost auditors, the adequacy of internal control systems, risk management systems.
- VI. Reviewing the adequacy of internal audit function, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.
- VII. Discussion with internal auditors any significant findings and follow up there on.
- VIII. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board.
- IX. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post audit discussion to ascertain any area of concern;
- X. Approval of appointment of CFO or the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing qualifications, experience and background, etc. of the candidate;
- XI. Reviewing the Company's financial and risk management policies.
- XII. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
- XIII. to review the functioning of the Vigil Mechanism/Whistle blower mechanism

#### 4. NOMINATION AND REMUNERATION COMMITTEE

a. The composition of the Nomination and Remuneration Committee as on 31.03.2023 and the details of the meetings attended by the Directors are given below:

Mr. Pramay A. Chhatra - Chairman

Mr. Umang A. Gosalia – Member

Ms. Ami Shah - Member

The Meetings of Nomination and Remuneration Committee were held on and 12.11.2022, and 14.02.2023

Name of Members	Total Meetings held during the year	No. of meetings attended
Mr. Pramay A. Chhatra	2	2
Mr. Umang A. Gosalia	2	2
Ms. Ami Shah	2	2

- b. Keeping in view the provisions of section 178 of the Act and the provisions of the SEBI LODR Regulations 2015, the terms of reference of the Nomination and Remuneration Committee include the following.
  - I. formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
  - II. formulation of criteria for evaluation of performance of independent directors and the board of directors;
  - III. devising a policy on diversity of board of directors;
  - IV. identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal;
  - V. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.

During the period under review No sitting fee is payable to the Executive, Non Executive and Managing Director.

c. Details of shares/convertible instruments held in the Company by the Non-Executive Directors.

Name	No. of Shares held
Mr. Pramay A Chhatra	Nil
Ms. Ami Shah	Nil

d. Details of pecuniary relationship or transactions of the Non-Executive Directors vis-avis the Company are given below:

Name of Members	Amount
Mr. Pramay A. Chhatra	Nil
Ms. Ami Shah	Nil

STAKEHOLDER RELATIONSHIP COMMITTEE (erstwhile Shareholders'/Investors' grievance committee):-

A. The Composition of Stakeholder Relationship Committee as on 31.03.2023 and details of committee meetings attended by Director are as under:-

Mr. Pramay A. Chhatra - Chairman

Mr. Umang A. Gosalia - Member

Ms. Ami Shah - Member

The Meeting of Stakeholder Relationship Committee was held on 20.08.2022, 06.10.2022, 14.12.2022, 22.12.2022, 16.02.2023 and 04.03.2023 and all the members were present in the meeting.

Name of Members	Total Meetings held during the	No. of meetings attended
	year	
Mr. Pramay A. Chhatra	6	6
Mr. Umang A. Gosalia	6	6
Ms. Ami Shah	6	6

- B. Keeping in view the provisions of section 178 of the Act, and the provisions of the SEBI LODR Regulations 2015 the terms of reference of the Stakeholders Relationship Committee are as follows:-
  - I. Oversee and review all matters connected with the transfer of the Company's securities;
  - II. Approve issue of the Company's duplicate share / debenture certificates;
  - III. Consider, resolve and monitor redressal of investors' / shareholders' / security holders' grievances related to transfer of securities, non-receipt of Annual Report, non-receipt of declared dividend etc.;
  - IV. Oversee the performance of the Company's Registrars and Transfer Agents;
  - V. Recommend methods to upgrade the standard of services to investors;
  - VI. Monitor implementation and compliance with the Company's Code of Conduct for Prohibition of Insider Trading;
- VII. Carry out any other function as is referred by the Board from time to time and / or enforced by any statutory notification / amendment or modification as may be applicable.

#### C. Investor Grievance Redressal:-

Number of complaints received and resolved during the year as on 31<sup>st</sup> March, 2023 is as follows:-

Number of complaints as on 1 <sup>st</sup> April, 2022	0
Number of complaints received during the year ended on 31 <sup>st</sup> March, 2023	0
Number of complaints resolved up to 31st March, 2023	0
Number of complaints pending as on 31st March, 2023	0

# **Managing Director and CFO Certification**

The Chairman/Managing Director and CFO have issued certificate pursuant to the provisions of under Regulation 17(8) of the (LODR) Reg, 2015 certifying that the financial statements do not contain any untrue statement and these statements represent a true and fair view of the Company's affairs. The said certificate is annexed and forms part of the Annual Report.

# **DEPOSITORY SYSTEM:**

As members are aware, the company's shares are compulsorily tradable in the electronic form. As on March 31, 2023 almost 72.03% of the Company's total paid-up capital representing 26,94,770 shares were in dematerialized form. In viewof the numerous advantages offered by the Depository system, members holding shares in physical mode are advised to avail of the facility of dematerialization on either of the Depositories

# **General Body Meetings**

Details of last three Annual General Meetings are as under:

Year	Date Date	Time	Venue	No. of Special Resolutions
				Passed and the brief of special resolution
2019-20	16/10/2020	2.00 PM	At Registered Office of the Company:  Plot No. 20, Survey No. 52, Rajkot- Gondal National	1. Approval of re- appointment of Mr. Alkesh Gopani as a Managing Director of the Company for a period of 2 years and revision in remuneration.
			Highway No. 27, Rajkot – 360311, Gujarat, India	<ol> <li>Approval of change in designation of Shri Alkesh Gosalia and Appointment as Managing Director for a period of 5 years and revision in remuneration.</li> <li>Approval of change in designation of Mr. Umang Alkesh Gosalia and Appointment as Whole- time Director for a period of 5 years and revision in remuneration</li> </ol>
2020-21	20/09/2021	2.00 PM	At Registered Office of the Company:  Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Rajkot – 360311, Gujarat, India	<ol> <li>Approval of change in designation of Dr. Umang Gosalia from Whole-time Director to Managing Director for a period of 5 years and revision in his remuneration.</li> <li>Re-appointment of Mr. Pramay Chhatra as an Independent Director for further period of 5 years.</li> <li>Re-appointment of Mrs. Asha Daftary as an Independent Director for further period of 5 years.</li> </ol>
2021-22	30/09/2022	2.00 PM	- do-	NIL

Company has not passed any Special or Ordinary resolution by way of Postal ballot or Extra Ordinary General Meeting during the Financial Year 2022-23.

#### INDEPENDENT DIRECTORS' MEETINGS

All the Independent Directors met on 25th March, 2023 to deliberate on some important matters concerning the Company, inter - alia, to evaluate the:

- (i) Performance of Non-Independent Directors and the Board as a whole;
- (ii) Performance of the Chairman of the Board, taking into account the views of the Executive and Non-Executive Directors; and
- (iii) Quality, content, and timeliness of flow of information between the Management and the Board that is necessary for the Board to act effectively and reasonably perform its duties.

#### **DISCLOSURES:**

- a) Disclosure on materially significant related party transactions:
   Full disclosure of related party transactions as per accounting standard 18 issued by The Institute of Chartered Accountants of India is given under Note No. 22 of Notes Forming part of accounts for the year ended on 31<sup>st</sup> March, 2023.
  - The Board has approved a policy for related party transactions which has been uploaded on the Company's website. The web-link as required under Listing Regulations is as under: http://www.parmaxpharma.com/policies.php
- b) No. penalties or strictures have been imposed on the Company by Stock Exchange or SEBI or any statutory authority on any matter related to capital Markets.
- d) Independent Directors are familiarised with their roles, rights and responsibilities in the Company as well as with the nature of industry and business model of the Company. The details of the familiarization programmes can be accessed on the web link: <a href="http://www.parmaxpharma.com/policies.php">http://www.parmaxpharma.com/policies.php</a>
- e) Proceeds from public issues, right issues, preferential issues, etc.: The Company did not raise any funds through public, rights, preferential issues, qualified institutional placement, etc. during the year under report.

Regulation 36(3) of SEBI (LODR) Regulations, 2015: Information relating to the Directors proposed to be appointed and those retiring by rotation and seeking re-appointment at this Meeting

Name	Umang A. Gosalia
Date of Birth	23/04/1984
DIN	05173830
No. of Equity Shares held inthe Company	1,00,000
Relationship with otherDirectors/ Manager /KMP	None
Education Qualification	M.Sc. and Doctorate in Organic (Chemistry)
Profile & Expertise in Specific functional Areas	Ph.D. (Doctorate in Organic (Chemistry) and having experience over a decade in chemistry & various types of organic reactions, and currently looking after the all production activities of the Company.
List of other Directorship / Committee membership in other Companies as on 31 <sup>st</sup> March, 2023.	None
Original date of appointment	02.01.2016

#### **MEANS OF COMMUNICATIONS**

### a) Financial Results:

The Company has regularly published its quarterly, half yearly & annual results in newspapers & submitted to stock exchanges in accordance with the Listing Agreement requirements. Company ordinarily published its quarterly reports in newspaper. Our Website address is <a href="http://www.parmaxpharma.com">http://www.parmaxpharma.com</a>.

#### b) Website:

The Company's website <a href="http://www.parmaxpharma.com">http://www.parmaxpharma.com</a> contains a separate dedicated section namely "Investors Relations" where shareholders information is available. The Annual Report of the Company is also available on the website of the Company.

# **GENERAL SHAREHOLDERS' INFORMATION:-**

# A. Annual General Meeting:-

**Date: -** 29<sup>th</sup> September, 2023 **Venue:-**Plot No. 20, Survey No. 52,

Rajkot-Gondal National Highway No. 27, Hadamtala,

Tal. Kotda Sangani, Dist. Rajkot – 360 311

Gujarat, India
Time: - 3:00 P.M.

# B. Financial Year: 2023-2024 (Tentative)

The financial year of the Company is 1<sup>st</sup> April to 31<sup>st</sup> March and financial results will be declared as per the following schedule.

Particulars	Tentative Schedule
Quarterly Unaudited Result	
Quarter Ending 30 <sup>th</sup> June, 2023	On 14 <sup>th</sup> August, 2023
Quarter Ending 30 <sup>th</sup> September, 2023	On or before 14 <sup>th</sup> November, 2023
Quarter Ending 31 <sup>st</sup> December, 2023	On or before 14 <sup>th</sup> February, 2024
Annual Audited Result	
Year ending 31 <sup>st</sup> March, 2024	Within 60 days from 31 March, 2024

# C. Date of Book Closure:

The Share Transfer Book and Register of Members will remain closed from 23<sup>rd</sup> September, 2023 to 29<sup>th</sup> September, 2023 (both days inclusive).

# D. Dividend: Nil

# E. Listing at following Stock Exchanges:

Name of the Stock Exchange	Stock Code
The BSE Limited (BSE)	540359
ISIN for Equity Shares held in Demat form with NSDL and CDSL	INE240T01014

# F. Listing Fees:

The Company has paid the listing fees to Bombay stock exchanges.

# G. Registrar & Share Transfer Agents:

Name & Address : Purva Sharegistry (India) Pvt. Ltd.

No-9, Shiv Shakti Industrial Estate, Ground Floor,

J. R. Boricha Marg, Opp. Kasturba Hospital,

Lower Parel, Mumbai - 400 011

Tele No.: 022-2301 6761 / 2301 8261Fax No.: 022-2301 2517

# H. Share Transfer System

 The Company's share transfer and related operations are currently being handled by Purva Sharegistry India Private Limited, Registrar and Share Transfer Agents (RTA) who are registered with the SEBI as a Category 1 Registrar.

# J. SHARE HOLDING PATTERN AS ON 31<sup>st</sup> MARCH, 2023:

Sr. No	Category	No. of Shares held	% of Share Holding
1	Promoters	1152450	30.80
2	Mutual Fund and UTI	0	0
3	Bank, Financial Institution, Insurance	0	0
	Companies (Central/State Government		
	Institution)		
4	Foreign Institutional Investors	0	0
5	Private Corporate Bodies	1707	0.04
6	Indian Public	2546182	68.06
7	HUF	34557	0.92
8	NRIs/OCBs	6404	0.18
9	GDR /ADR	0	0
10	Clearing Member	0	0.00
	Grand Total :-	3741300	100.00

K. Outstanding GDR/ADRs/ Warrant or any convertible instrument, conversion and likely impact on equity:-NIL


L. Name of Company Secretary: CS Yash Vora

# M. Distribution of Shareholding as on 31<sup>st</sup> March, 2023

SHAREHOLDING OF	NUMBER	% OF TOTAL	IN RS	% OF TOTAL
NOMINAL VALUE				
UPTO 5,000	1492	74.71	1664400	4.44
5,001 - 10,000	137	6.86	1186340	3.17
10,001 - 20,000	90	4.50	1462260	3.90
20,001 - 30,000	186	9.31	4748540	12.69
30,001 - 40,000	24	1.20	888940	2.37
40,001 - 50,000	34	1.70	1674400	4.47
50,001 - 1,00,000	17	0.85	1205740	3.22
1,00,001 & ABOVE	17	0.85	24582380	65.70
TOTAL =>	1997	100	37413000	100

# N. Market Price Data of equity shares of the Company

Parmax Highest Share Price	BSE	Month
47	60786.07	Apr-22
42.95	57184.21	May-22
41.8	56432.65	Jun-22
34.5	57619.27	Jul-22
34.5	60341.41	Aug-22
35	60676.12	Sep-22
43.9	60786.7	Oct-22
39	63303.01	Nov-22
57.6	63583.07	Dec-22
40.95	61343.96	Jan-23
39.6	61682.25	Feb-23
34.6	60498.48	Mar-23



# O. Registered Office Address for Correspondence

# Parmax Pharma Limited

Plot No. 20, Survey No. 52,

Rajkot-Gondal National Highway No. 27,

Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311, Gujarat, India

Website: <a href="www.parmaxpharma.com">www.parmaxpharma.com</a>
Email Id: <a href="mailto:info@parmaxpharma.com">info@parmaxpharma.com</a>
Phone Number: - 02827 – 270534/270535

For Parmax Pharma Limited

Date: 14<sup>th</sup> August, 2023

Place: Rajkot

Dr. Umang Gosalia Managing Director DIN: 05153830

# **Declaration of compliance with the Code of Conduct:**

Pursuant to Regulation 26(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Members, Parmax Pharma Limited Hadamtala, Dist. Rajkot

I, Dr. Umang Gosalia, Managing Director, of Parmax Pharma Limited hereby declare that all the board members and senior executives one level below the executive directors including all functional heads have affirmed for the financial year ended 31<sup>st</sup> March, 2023, compliance with the code of conduct of the Companylaid down for them.

For Parmax Pharma Limited

Date: 14<sup>th</sup> August, 2023

Place: Rajkot

Dr. Umang Gosalia Managing Director DIN: 05153830

# Chief Executive Officer (CEO) / Chief Financial Officer (CFO) Certification under Regulation 17(8) of the (LODR) Regulation 2015

To, The Board of Director Parmax Pharma Limited. Hadamtala, Rajkot.

We, Umang Alkesh Gosalia, Managing Director in terms of Companies Act, 2013 and Keyur D. Vora, Chief Financial Officer of the Company hereby certify to the Board that:

- **A.** We have reviewed financial statements and the cash flow statement of Parmax Pharma Limited for the year ended 31<sup>st</sup> March, 2023 and to the best of our knowledge and belief:
  - 1. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  - **2.** These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- **B.** There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting. We have not come across any reportable deficiencies in the design or operation of such internal controls.
- **D.** We have indicated to the auditors and the Audit committee:
  - 1. That there are no significant changes in internal control over financial reporting during the year;
  - 2. That there are no significant changes in accounting policies during the year; and
  - **3.** That there are no instances of significant fraud of which we have become aware.

Date: 30.05.2023

Place: Rajkot Dr. Umang Gosalia Keyur D. Vora

Managing Director Chief Financial Officer

# Certificate regarding compliance of conditions of Corporate Governance

To, The Members, Parmax Pharma Limited

We have examined the compliance of the conditions of Corporate Governance by M/s. Parmax Pharma Limited (the Company) for the year ended 31<sup>st</sup> March 2023, as stipulated in regulation 17 to 27 and 23 (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the period from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023.

- 1. The Compliance of the conditions of Corporate Governance is the responsibility of the Company's Management. Our examination was limited to the procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of an opinion on the financial statements of the Company.
- 2. In our opinion and to the best of our information and according to our examination of the relevant records and the explanations made by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in clause 49 of Listing Agreement and regulation 17 to 27 and clauses (b) to (i) of Regulation 46 (2) and para C,D and E of Schedule V of the Listing Regulations for the respective periods of applicability as specified under the paragraph 1 above, during the year ended on March 31, 2023.
- 3. In our opinion and to the best of our information and according to the explanation given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI (LODR) Regulations, 2015.
- 4. We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

Place: Ahmedabad Date: 14.08.2023 Samsad Alam Khan Company Secretaries

CP No: 13972

UDIN: A028719E000909082

# Independent Auditor's Report

To the Members of Parmax Pharma Limited

# **Report on the Audit of the Standalone Financial Statements**

# **Opinion**

We have audited the IND AS financial statements of **Parmax Pharma Limited** ("the Company"), which comprise the balance sheet as at **31st March 2023**, and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the IND AS financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid IND AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2023, its loss and its cash flows for the year ended on that date.

# **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the IND AS Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the IND AS financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexure to Board's Report but does not include the IND AS financial statements and our auditor's report thereon.

Our opinion on the IND AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the IND AS financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the IND AS financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

# **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the IND AS financial statements of the current period. These matters were addressed in the context of our audit of the IND AS financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

In Current Year the management of Company has decided to write off its all pre-operative expenses which are forming the part of Balance Sheet amounting to Rs. 1,98,06,997/- as on 01-04-2019 equally in 5 years. Total Pre-operative expenses Written off during the year under Audit FY 2022-23 is Rs. 39,61,400 and same is forming part of Other Expenses in standalone financial statements forming part of this report.

# Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these IND AS financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards (IND AS) specified under section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the IND AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the IND AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

# Auditor's Responsibilities for the Audit of the IND AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the IND AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these IND AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the IND AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence

that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the IND AS financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the IND AS financial statements, including the disclosures, and whether the IND AS financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the IND AS financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

# **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure B', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

29<sup>th</sup> Annual Report Parmax Pharma Limited

2. As required by Section 143 (3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit subject to above opinion.

- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid IND AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 subject to above Opinion.
- e) On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.
- g) With respect to the matter to be included in the Auditor's Report under section 197(16), In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under section 197(16) which are required to be commented upon by us.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - The Company does not have any pending litigations which would impact its financial position.
  - The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For B A Shah S R Mehta & Co **Chartered Accountants** 

FRN: 128796W

Place:-Rajkot Date: 30/05/2023

UDIN:23159526BGYPIN1016

Malay Shah (Partner)

Membership No. 159526

Annexure 'A'

# Report on Internal Financial Controls Over Financial Reporting

# Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of PARMAX PHARMA LIMITED ("the Company") as of March 31, 2023 in conjunction with our audit of the IND AS financial statements of the Company for the year ended on that date.

# **Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

# **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the IND AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of IND AS financial statements for external purposes in accordance with generally accepted accounting principles (IND AS). A company's internal financial control over financial reporting includes those policies and procedures that

- 1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of IND AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- 3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the IND AS financial statements.

# Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For B A Shah S R Mehta & Co. Chartered Accountants FRN: 128796W

Malay Shah

(Partner)

Membership No. 159526

Place:-Rajkot Date: 30/05/2023

UDIN:23159526BGYPIN1016

Annexure 'B'

# The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".

We report that:

- (i) (a) (A) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;
  - (B) The Company does not have any intangible assets. Accordingly, clause 3(i)(a)(B) of the Order is not applicable to the Company.
  - (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Property, Plant and Equipment have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification;
  - (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favor of the lessee) disclosed in the financial statements are held in the name of the company,
  - (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets during the year. Accordingly, the reporting under Clause 3(i)(d) of the Order is not applicable to the Company.
  - (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- (ii) (a) As explained to us & on the basis of the records examined by us, in our opinion, physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancy of 10% or more in the aggregate for each class of inventory were noticed on physical verification of stocks by the management as compared to book records.
  - (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not been sanctioned during any point of time of the year, working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not made investments in, nor provided any guarantee or security or granted any loans or advances in the nature of loans,

secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year. Accordingly, provisions of clause 3(iii)(a), 3(iii)(b), 3(iii)(c), 3(iii)(d), 3(iii)(e) and 3(iii)(f) of the Order are not applicable to the Company.

- (iv) According to the information and explanations given to us and on the basis of our examination of the records, in respect of loans, investments, guarantees, and security, provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.
- (v) The company has accepted deposits of Rs. 25 lacks from Relative of Directors and Hence directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of deposit) Rules, 2015 with regard to the deposits accepted from the relative of Director is contravening. According to information and explanations provided to us, no order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other tribunal.
- (vi) As per information & explanation given by the management, maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act.
- (vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. According to the information and explanation given to us there were no outstanding statutory dues as on 31st of March, 2023 for a period of more than six months from the date they became payable. Except:

Name of the Statue	Nature of the Dues	Amount (Rs.)	Period for which the amount relates	Due Date	Date of Payment	Remarks, if any
INCOME TAX 1961	TDS	320000	FY 2021-22	07/04/2022	-	No Payment made
INCOME TAX 1961	TDS	25000	FY 2022-23	07/06/2022	-	No Payment made
INCOME TAX 1961	TDS	25000	FY 2022-23	07/07/2022	-	No Payment made
INCOME TAX 1961	TDS	25000	FY 2022-23	07/08/2022	-	No Payment made

(b) According to the information and explanations given to us, there is no amount payable in respect of income tax, Goods and service tax, Service Tax, sales tax, customs duty, excise duty, value added tax and cess whichever applicable, which have not been deposited on account of any disputes.

- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.
- (ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender
  - (b) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not been declared a willful defaulter by any bank or financial institution or other lender;
  - (c) According to the information and explanations given to us by the management, the Company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained,
  - (d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short term basis have been used for long term purposes by the company.
  - (e) The Company does not hold any investment in any subsidiary, associate or joint venture (as defined under the Act) during the year ended 31 March 2023. Accordingly, clause 3(ix)(e) is not applicable.
  - (f) In our opinion and according to the information and explanations given by the management, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Accordingly, clause 3(ix)(f) is not applicable.
- (x) (a) Based on our audit procedures and according to the information given by the management, moneys raised by way of initial public offer or further public offer (including debt instruments) during the year were applied for the purposes for which those are raised.
  - (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- (xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the company or any fraud on the company has been noticed or reported during the course of audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;

- (c) According to the information and explanations given to us by the management, no whistle-blower complaints had been received by the company.
- (xii) The company is not a Nidhi Company. Accordingly, clause 3(xii)(a), 3(xii)(b) and 3(xii)(c) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, where applicable and the details have been disclosed in the financial statements, as required by the applicable accounting standards;
- (xiv) (a) Based on information and explanations provided to us and our audit procedures, the company has an internal audit system commensurate with the size and nature of its business;
  - (b) We have considered the internal audit reports of the Company issued till date for the period under audit.
- (xv) In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with directors or persons connected with him and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company
- (xvi) (a) In our Opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934). Accordingly, clause 3(xvi)(a) of the Order is not applicable.
  - (b)In our Opinion and based on our examination, the Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
  - (c) In our Opinion and based on our examination, the Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
  - (d) According to the information and explanations given by the management, the Group does not have any CIC as part of the Group.
- (xvii) Based on our examination, the company has not incurred cash losses in the financial year and in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

29<sup>th</sup> Annual Report Parmax Pharma Limited

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

- (xx) Based on our examination, the provision of section 135 are not applicable on the company. Accordingly, clause 3(xx)(a) and 3(xx)(b) of the Order are not applicable.
- (xxi) The company is not required to prepare Consolidate financial statement hence this clause is not applicable.

For B A Shah S R Mehta & Co. **Chartered Accountants** 

FRN: 128796W

Place:-Rajkot Date: 30/05/2023

UDIN:23159526BGYPIN1016

Malay Shah (Partner)

Membership No. 159526

# Statement of Assets and Liabilities as on 31.03.2023

(in Rs Hundreds.)

Particulars		Note	As at	As at
		No.	31.3.2023	31.3.2022
	-1-			
I. Asse				
1. Non-cur	rent assets (a) Property, Plant and Equipment	1	0.50.040.05	10 11 255 20
	(b) Capital work-in-progress	1	9 ,50,048.07	10,44,265.39
			-	
	(c) Investment Property (d) Goodwill		<u>-</u>	
	(d) Goodwill (e) Other Intangible assets		-	
	(f) Intangible assets under development		-	<del>-</del>
			-	
	(g) Biological Assets other than bearer plants		-	-
(1-)	·			
(h)	Financial Assets (i) Investments	2	60.00	60.00
	(ii) Trade receivables		-	
	(iii) Loans	3	18,658.36	17,952.19
(i)	Deferred tax assets (net)	22	10,030.30	17,332.13
(i)	Other non-current assets	4	39,613.97	79,227.97
	al Non-Current Assets	-	10,08,380.40	11,41,505.55
-	nt assets			
Z. Curre	(a) Inventories	5	4 ,30,610.56	2,85,249.93
	(b) Financial Assets	_		, ,
	(i) Investments			
	(ii) Trade receivables	6	62,274.49	67,689.84
	(iii) Cash and cash equivalents	7	40,679.08	1,05,425.19
	(iv) Bank balances other than(iii) above	<u> </u>	•	
	(v) Loans	8	2,19,318.62	1,97,600.83
	(vi) Others (to be specified)	_	-	
	(c) Current Tax Assets (Net)	_	-	_
	(d) Other current assets	_	-	
	Total Current Assets		7,52,882.75	6,55,965.78
	Total Assets		17,61,263.15	17,97,471.33
II. Equ	ity and Liabilities			
	1. Equity			
	(a) Equity Share capital	9	4,45,115.00	4,45,115.00
	(b) Other Equity	10	1,40,471.13	1,50,877.96
	Total Equity		5,85,586.13	5,95,992.96
	2. LIABILITIES			
ı. Non	n-current liabilities			
	(a) Financial Liabilities		4.47.000.00	4.50.62:.22
_	(i) Borrowings	11	4,47,909.03	4,52,324.82
_	(ii) Trade payables -		-	
_	(iii) Other financial liabilities -		-	-
	(other than those specified in			
_	item (b), to be specified)			

	Tota	l Equity	and Liabilities		17,61,263.15	17,97,471.33
		Total	of Current Liabilities		7,13,661.22	7,31,417.59
	(d)		d tax liabilities (Net)	-	-	-
	(c)	Provisi		14	96,871.16	9 3,363.33
	(b)	Other o	current liabilities-	13	1,50,370.83	8 5,943.53
	•		to be specified)			
			(other than those specified in item (b),			
		(xxiv)	Other financial liabilities	-	-	-
		(xxiii)	Trade payables	12	4,66,419.23	5,52,110.74
		(xxii)	Borrowings	-	-	-
	(a)	Financi	al Liabilities			
II.		Current	liabilities		, , , , , , , , , , , , , , , , , , , ,	, .,
	<u> </u>		-Current Liabilities		4,62,015.80	4,70,060.77
	(d)	Other n	on-current liabilities-		- -	_
	(c)	Deferre	d tax liabilities (Net)		14,106.77	17,735.95
	(b)	Provisio	ons-		-	-

Accounting policies	22	
Other Explanatory notes	23, 24	

For B A Shah S R Mehta & Co. *Chartered Accountants* 

Firm Registration No.: 128796W

For Parmax Pharma Limited

Dr. Umang Gosalia Managing Director DIN: 05153830

Nikhil S Uchat Director DIN: 08427983

Malay Shah Partner

Membership No. 159526 UDIN: 23159526BGYPIN1016

Date : 30.05.2023 Place : Rajkot Keyur Vora CFO Yash Vora Company Secretary

Date : 30.05.2023 Place : Rajkot

# Statement of Profit and Loss Account

(in Rs Hundreds.)

			,	unureus.,
Sr. No.	Particulars	Note	Year Ended	Year Ended
			31.03.2023	31.03.2022
			(Audited)	(Audited)
l.	Revenue from operations	15	1 5,42,434.50	18,25,111.98
II.	Other income	16	3 ,972.13	6 ,278.08
III.	Total Income (I+II)		15,46,406.63	18,31,390.05
	Expenses			
	(a) Cost of materials consumed	17	5,51,363.50	6,71,794.04
	(b) Purchase of stock-in-trade		-	<u>-</u>
IV.	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	18	(2100.00)	(610.00)
	(d) Employee benefits expense	19	2,80,179.65	3,46,160.65
	(e) Finance Costs	20	36,905.40	3 8,581.20
	(f) Depreciation and amortization expense	1	1,87,857.21	1,93,208.93
	(g) Other expenses	21	4,87,588.55	5,51,928.24
	Total expenses (IV)		15,41,794.32	18,01,063.06
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)		4,612.31	30,327.00
VI	Exceptional Items		-	-
VII	Profit/ (Loss) before tax (V-VI)		4,612.31	30,327.00
	Tax expense:			
VIII	(1) Current tax		18,500.00	22,500.00
	(2) Deferred tax		(3,629.18)	(5,353.29)
	(3)Current tax expenses relating to prior year		148.32	(971.04)
IX	Profit / (Loss) for the period from continuing operations (VII-VIII)		(10,406.83)	14,151.33
X	Profit/(loss) from discontinued operations		-	-
ΧI	Tax expense of discontinued operations			_
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-	_
XIII	Profit (Loss) for the period (IX+XII)		(10,406.83)	14,151.33
XIV	Other Comprehensive Income  A. (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss  B. (i) Items that will be reclassified to profit or loss (ii) income tax relating to items that will be reclassified to profit or loss		-	-
χV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)		(10,406.83)	14 151 22
XVI	Paid-up equity share capital (Face Value Rs 10)		37,413.00	<b>14,151.33</b> 37,413.00
	Earnings per share (for continuing operation)			<u> </u>
XVII	(of Rs. 10/- each ):			

29<sup>th</sup> Annual Report Parmax Pharma Limited

	(a) Basic			(0.28)	0.38
	(b) Diluted			-	-
	Earnings per share (for discontinuing operation)				
	(of Rs. 10/- each ):				
XVII	(a) Basic		-	-	
	(b) Diluted		-	_	
	Earnings per share (for continuing operation & discontinuing operation)				
	(of Rs. 10/- each ):				
XVII	(a) Basic			(0.28)	0.38
	(b) Diluted		-		-
	Accounting policies	22			

For B A Shah S R Mehta & Co. **Chartered Accountants** 

Firm Registration No.: 128796W

Malay Shah Partner

Membership No. 159526 UDIN: 23159526BGYPIN1016

Date : 30.05.2023 Place : Rajkot

For Parmax Pharma Limited

Dr. Umang Gosalia **Managing Director** 

Nikhil S Uchat Director DIN: 05153830 DIN: 08427983

Keyur Vora CFO

Date : 30.05.2023 Place : Rajkot

Yash Vora Company Secretary

# Cash Flow Statement for the year ended 31st March , 2023

( Amt. Hundreds)

	PARTICULARS		Period Ended on 31.03.2023	Period Ended or 31.03.202
<u>(A</u> )	CASH FLOW FROM OPERATING ACTIVITIES			
	Net Profit After Extraordinary Item but Before Taxation:		4,612.31	30,327.00
	Adjustments for:		4,012.31	30,327.00
	Depreciation		1,87,857.21	1,93,208.93
	Provision for Current Tax		18,500.00	22,500.00
	Current tax expenses relating to prior year		148.32	(971.04
	Provision for Deferred Tax Assets		(3629.18)	(5,353.29
	Operating profit before Working Capital changes		1,73,821.20	2,02,006.9
	Adjustments for changes in Working Capital:			
	(Increase) / Decrease in Inventories		(1,45,360.63)	1,10,064.0
	(Increase) / Decrease in Trade & Other Receivables		5,415.35	97,735.3
	(Increase) / Decrease in Short term Loans and Advances		(21,717.79)	20,944.2
	Increase / (Decrease) in Current Liabilities		(21,264.21)	(4,02,742.22
	Increase / (Decrease) in Provisions		3,507.83	9,607.4
	(Increase) / Decrease in Non Current Assets		39,614.00	39,614.0
	(Increase) / Decrease in Long term Loans & Advances		(706.17)	(2,285.25
	Cash generated from Operations		(1,40,511.63)	(1,27,062.32
	Net Cash from Operating activities	(A)	33,309.58	74,944.6
<u>(B)</u>	CASH FLOW FROM INVESTING ACTIVITIES			
	Purchase of Fixed Assets		(93,639.89)	(1,53,159.92
	Net Cash from / (Used in) Investing activities	(B)	(93,639.89)	(1,53,159.92
(C)	CASH FLOW FROM FINANCING ACTIVITIES			
	Increase / (Decrease) in other Long Term Borrowings		(4,415.79)	(91,004.33
	(Increase )/ Decrease in Non Current Investment			
	Net Cash (Used in) Financing activities	(C)	(4,415.79)	(91,004.33
	Net Increase in Cash & Cash Equivalents		(64,746.10)	(1,69,219.61
	(A + B + C) Cash & Cash Equivalents at the beginning of the year		1,05,425.17	2,74,644.7
	Cash & Cash Equivalents at the end of the year		40,679.07	1,05,425.1
	cash & cash Equivalents at the end of the year		40,073.07	1,03,423.17
For E	3 A Shah S R Mehta & Co.	For Parmax Pharma Limited		
	tered Accountants			
Firm	Registration No.: 128796W	Dr. Umang Gosalia	Nikhil S Ucha	t
		Managing Director DIN: 05153830	Director DIN: 0842798	3
Mala	y Shah	2.11. 0010000	2.11. 00-2730	· <b>-</b>
Parti	•			
	nbership No. 159526	Keyur Vora	Yash Vora	
	N: 23159526BGYPIN1016	CFO	Company Sec	cretary
Date Place		Date : 30.05.2023 Place : Rajkot		

# CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2023

( Amt. Hundreds)

	Period Ended on 31/03/2023	Period Ended on 31/03/2022
Cash & Cash Equivalents at the beginning of the year		
Cash on Hand	2,391.31	2,513.91
Balances with Scheduled Banks in Current & Deposit Account	1,03,033.88	2,72,130.88
	1,05,425.19	2,74,644.79
Cash & Cash Equivalents at the end of the year		
Cash on Hand	3,057.87	2,391.31
Balances with Scheduled Banks in Current & Deposit Account	37,621.21	1,03,033.88
	40,679.08	1,05,425.19
Net Increase / (Decrease)	(64,746.11)	(1,69,219.60)

Note: The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Accounting Standard - 3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India.

Parmax Pharma Limited

# Notes forming part of Balance Sheet as at 31.03.2023

1. FIXED ASSETS (Amt. Hundreds

1. FIXED ASSETS				E 1	Y. 2022-23					(	Amt. Hundreds)
				F.	1.2022-23						
	Depriciation		Gross	Block		Depreciation/Amortisation			Net Block		
Nature of Fixed Assets	Rate	As At 01.04.2022	Addition during the year	Disosal/ Deducation	As at 31.03.2023	As at 01.04.2022	Provided during the year	Disposal/ Deducation	As at 31.03.2023	As at 31.03.2023	As at 31.03.2022
(A) TANGIBLE ASSETS:											
AHU PLANT	18.10%	400.00	_	_	400.00	249.90	27.17		277.07	122.93	150.10
AIR CONDITIONER	18.10%	7,132.54	404.09	-	7,536.63	3,800.06	620.80	-	4,420.86	3,115.77	3,332.48
BOREWELL	45.07%	2,199.44	-	-	2,199.44	2,089.45	49.57	-	2,139.02	60.42	109.99
BUILDING (FACTORY)	9.50%	1,74,376.87	1,278.05	-	1,75,654.92	49,166.67	11,977.18	-	61,143.85	1,14,511.07	1,25,210.20
CCTV CAMERA SYSTEM	39.30%	11,872.83	190.00	-	12,062.83	6,465.70	2,143.67	-	8,609.37	3,453.46	5,407.13
COMPOUND WALL	9.50% 39.30%	19,169.00 5,206.89	1,065.00 285.30	-	20,234.00	7,531.96	1,139.24 496.62		8,671.20 4.525.44	11,562.80 966.76	11,637.04
COMPUTER COOLING TOWER	18.10%	6,252.38	285.30	-	5,492.20 6,252.38	4,028.82 2,592.27	662.48		3,254.75	2,997.63	1,178.07 3,660.11
CLEAN ROOM PLANT	18.10%	4,61,243.71	2,003.85		4,63,247.56	1,60,760.48	54,659.49		2,15,419.97	2,47,827.59	3,00,483.22
DEEPWEL PUMP	45.07%	1,400.00	-	_	1,400.00	1,325.20	33.71	_	1,358.91	41.09	74.80
DISPLAY SIGN BOARD	18.10%	1,992.00	-	_	1,992.00	1,176.87	147.54	_	1,324.41	667.59	815.13
EFFLUENT TREATMENT PLANT	18.10%	26,380.26	-	-	26,380.26	15,444.43	1,979.39	-	17,423.82	8,956.45	10,935.83
ELECTRIC INSTALLATION	25.89%	37,670.85	4,308.63	-	41,979.48	25,365.76	3,654.93	-	29,020.70	12,958.78	12,305.09
ELECTRIC TRANSFORMER & SWITCH	25.89%										
GEAR A/C.		10,500.00	-	-	10,500.00	8,084.33	625.42	-	8,709.75	1,790.25	2,415.67
FACTORY EQUIPMENTS	25.89% 18.10%	1,637.75 1,379.16	555.00	_	2,192.75 1,379.16	986.36 833.34	201.01 98.79	-	1,187.37 932.13	1,005.38 447.03	651.39 545.82
FIRE EXTINGUISHERS	18.10%	878.50	_		1,379.16 878.50	370.20	92.00		462.20	416.30	508.30
FURNITURE & FITTINGS	25.89%	27,881.81	206.04	_	28,087.85	20,384.41	1,945.52	_	22,329.93	5,757.92	7,497.40
GENERATOR SET	18.10%	20,500.00	-	_	20,500.00	7,630.85	2,329.32	_	9,960.17	10,539.83	12,869.15
GODOWN	9.50%	800.00	-	_	800.00	310.10	46.54	-	356.64	443.36	489.90
HYDRAULIC EQUIPMENTS	18.10%	150.00	-	-	150.00	93.72	10.19	-	103.91	46.09	56.28
LAB EQUIPMENTS	25.89%	28,761.61	2,283.50	-	31,045.11	17,845.50	3,247.67	-	21,093.17	9,951.94	10,916.11
LAND & SITE DEVELOPMENT	0.00%	20,534.40	-	-	20,534.40	-	-	-	-	20,534.40	20,534.40
LAWN MOVER	18.10%	120.00	-	-	120.00	74.97	8.15	-	83.12	36.88	45.03
MISC. FIXED ASSETS	18.10% 18.10%	38.50 2,716.00	699.06	_	38.50 3,415.06	24.32 1,587.77	2.57 222.52	-	26.88 1,810.29	11.62 1,604.77	14.18 1,128.23
MONO BLOCK PUMP A/C. MOTOR CAR CHEVROLET CRUZE	31.23%	2,500.00	699.06		2,500.00	2,100.91	124.64		2,225.55	274.45	399.09
MOTOR CAR HYUNDAI CRETA	31.23%	7,000.00	_	_	7,000.00	5,882.55	348.98	_	6,231.53	768.47	1,117.45
MOTOR CAR MERCEDES BENZ	31.23%	25,000.00	_	_	25,000.00	21,009.14	1,246.35	_	22,255.49	2,744.51	3,990.86
MOTOR CAR NISSAN TERRANO	31.23%	4,500.00	-	-	4,500.00	3,781.64	224.34	-	4,005.98	494.02	718.36
MOTOR CAR SWIFT DZIRE	31.23%	1,500.00	-	-	1,500.00	1,260.54	74.78		1,335.32	164.68	239.46
MOTOR CAR KIA SELTOS	31.23%	15,152.75	-	-	15,152.75	8,546.61	2,063.10	-	10,609.70	4,543.05	6,606.14
OFFICE EQUIPMENT	45.07%	709.48	-	-	709.48	676.45	14.89	-	691.34	18.14	33.03
PLANT & MACHINERIES	18.10%	7,74,361.03	78,529.50	-	8,52,890.53	2,98,739.48	94,015.60	-	3,92,755.08	4,60,135.45	4,75,621.55
REFRIGERATOR	18.10%	885.22	304.24	-	1,189.46	429.37	132.99	-	562.36	627.10	455.85
RM STORE STACK	18.10%	3,363.60	840.00	-	4,203.60	941.31	565.13	-	1,506.45	2,697.15	2,422.29
RO WATER PURIFIER STAFF QUARTERS	18.10% 9.50%	7,046.00 19,700.00	630.00		7,676.00 19,700.00	4,315.54 7,635.98	589.24 1,146.08		4,904.78 8,782.06	2,771.22 10,917.94	2,730.46 12,064.02
STORAGE EQUIPMENTS	18.10%	5,718.47		[	5,718.47	3,611.30	381.40	:	3,992.69	1,725.78	2,107.17
TEA VENDING MACHINE	18.10%	80.00		-	80.00	49.98	5.43		55.41	24.59	30.02
TELEPHONE	18.10%	5,584.37	57.63	_	5,642.00	2,992.67	472.58		3,465.25	2,176.75	2,591.70
TESTING MACHINE & PARTS	18.10%	60.00	-	-	60.00	37.49	4.07	-	41.56	18.44	22.51
TOOLS	18.10%	391.81	-	-	391.81	247.44	26.13	-	273.57	118.24	144.37
TOTAL (A)		17,44,747.24	93,639.89	-	18,38,387.13	7,00,481.85	1,87,857.21	-	8,88,339.06	9,50,048.07	10,44,265.39
(B) INTANGIBLE ASSETS:											
TOTAL (B)		-	-	-	-	-	-	-	-	-	-
C ) CAPITAL WORK-IN-PROGRESS											
(at cost):		-	-	-	-	-	-	-	-	-	-
New Project A/c (Building & Constru		-	-		-	-	-	-	-	-	-
New Project A/c (Plant & Machinery	)	-	-			-	-		-	-	-
Project Pre Operative Exp		-	-		_	_	_	-	-	-	-
TOTAL (C)		-	-	-	-	-	-	-	-	-	-
TOTAL (A+B+C)		17,44,747	93,640	-	18,38,387	7,00,482	1,87,857	-	8,88,339	9,50,048	10,44,265
31.03.2022		15,91,587	1,53,310	150	17,44,747	5,07,273	1,93,209	-	7,00,482	10,44,265	10,84,314

(in Rs Hundreds.)

National Saving Certificate   60.00			As at March 31, 2023	As at March 31, 2022
National Saving Certificate 60.00 60.00  7	2. NON-CURRENT INVESTMENTS			
Security deposits   18658.36   17952.19     Security deposits   18658.36   17952.19     Security deposits   18658.36   17952.19     A. OTHER NON CURRENT ASSETS   39613.97   79227.97     Miscellaneous Expenses   39613.97   79227.97     Total   39613.97   79227.97     Total   39613.97   79227.97     S. INVENTORIES   114500.50   172805.11     Stores & Consumables   6600.00   4500.00     Work in Process   309510.06   1079344.82     S. TRADE RECEIVABLES   6600.00   4500.00     Work in Process   309510.06   1079344.82     S. TRADE RECEIVABLES   57121.37   67684.27     Cast an air months   5153.12   5.57     Unsecured, Considered Good   57121.37   67684.27     S. TRADE RECEIVABLES   0	<b>Unquoted Investment</b> National Saving Certificate		60.00	60.00
Unsecured and considered good   18658.36   17952.19		Total	60.00	60.00
Total   18658.36   17952.19	3. LONG-TERM LOANS AND ADVANCES			
Note   18658.36   17952.19   17952.19   18658.36   17952.19   17952.19   18658.36   17952.19   17	(Unsecured and considered good)			
A. OTHER NON CURRENT ASSETS  Miscellaneous Expenses  Miscellaneous Expenses  Total  39613.97 79227.97  Total 39613.97 79227.97 79227.97  Total 39613.97 79227.97  Total 14500.50 107944.82 Total 430610.56 285249.93  Total 285	Security deposits		18658.36	17952.19
Miscellaneous Expenses   39613.97   79227.97   7018   39613.97   79227.97   7018   39613.97   79227.97   7018   39613.97   79227.97   7018		Total	18658.36	17952.19
Total   39613.97   79227.97   7	4. OTHER NON CURRENT ASSETS			
S.INVENTORIES   114500.50   172805.11   172805.12	Miscellaneous Expenses		39613.97	79227.97
Raw material 114500.50 172805.11 15tores & Consumables 6600.00 4500.00 309510.06 107944.82 150.00 309510.06 107944.82 150.00 309510.06 107944.82 150.00 309510.06 107944.82 150.00 309510.06 107944.82 150.00 309510.06 107944.82 150.00 1509510.06 107944.82 150.00 1509510.06 150		Total	39613.97	79227.97
Stores & Consumables   Stores & Consumables & Consumables   Stores & Consumables & Consuma				
Nork in Process   309510.06   107944.82	Raw material			172805.11
6. TRADE RECEIVABLES (Unsecured and considered good ) Less than six months Unsecured, Considered Good 57121.37 67684.27 6-12 Months Unsecured, Considered Good 5153.12 5.57 Unsecured, Considered Good 0 12 Months - 24Months 0 Unsecured, Considered Good 0 24 Months - 36Months 0 Unsecured, Considered Good 0 24 Months - 36Months 0 Unsecured, Considered Good 0 25 Word of the state of t		Total	309510.06	107944.82
Unsecured, Considered Good 57121.37 67684.27  6-12 Months Unsecured, Considered Good 12 Months - 24Months Unsecured, Considered Good 24 Months - 36Months Unsecured, Considered Good 24 Months - 36Months Unsecured, Considered Good 25 Months - 36Months Unsecured, Considered Good 26 Months - 36Months Unsecured, Considered Good 27 Months - 36Months Unsecured, Considered Good 28 Months - 36Months Unsecured, Considered Good Total  7 CASH AND CASH EQUIVALENTS Cash on hand Bank Balance - Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  21550.00 21500.00	(Unsecured and considered good )			
5-12 Months Unsecured, Considered Good Exceeding 3 Years Unsecured, Considered Good Unsecured, Conside			57121.37	67684.27
Unsecured, Considered Good 12 Months - 24Months Unsecured, Considered Good 24 Months - 36Months Unsecured, Considered Good 25 Months - 36Months Unsecured, Considered Good 26 Months - 36Months Unsecured, Considered Good Exceeding 3 Years Unsecured, Considered Good			5452.42	F F.7
Unsecured, Considered Good 24 Months - 36Months Unsecured, Considered Good Exceeding 3 Years Unsecured, Considered Good  Total  CASH AND CASH EQUIVALENTS Cash on hand Bank Balance - Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  Quarantee With HDFC Bank)			5153.12	5.57
24 Months - 36Months Unsecured, Considered Good Exceeding 3 Years Unsecured, Considered Good  Total  Total  62274.49 67689.84  7. CASH AND CASH EQUIVALENTS Cash on hand Bank Balance - Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  21550.00 21500.00				0
Unsecured, Considered Good Exceeding 3 Years Unsecured, Considered Good Unsecured, Considered Good  Total  Total  62274.49 67689.84  7. CASH AND CASH EQUIVALENTS Cash on hand Bank Balance - Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  21550.00 21500.00			C	
Unsecured, Considered Good  Total  Total  62274.49 67689.84  7. CASH AND CASH EQUIVALENTS Cash on hand Bank Balance  - Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  21550.00 21500.00			r	
Total 62274.49 67689.84  7. CASH AND CASH EQUIVALENTS Cash on hand Bank Balance - Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)	Exceeding 3 Years		·	0
7. CASH AND CASH EQUIVALENTS Cash on hand Bank Balance - Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  3057.87 2391.31 81533.88 16071.21 81533.88 21533.88 21533.88	onsecuteu, consucteu doou		C	
Cash on hand Bank Balance  - Balance with banks - HDFC Fixed Deposit  Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  3057.87 2391.31 81533.88 16071.21 81533.88  - HDFC Fixed Deposit  Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)		Total	62274.49	67689.84
- Balance with banks - HDFC Fixed Deposit Earmarked Balances with banks (Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  16071.21 81533.88  16071.21 81533.88  21533.88  21533.88	Cash on hand		3057.87	2391.31
(Balancesheld as margin money against guarantees Bank Guarantee with HDFC Bank)  21550.00 21500.00	<ul><li>- Balance with banks</li><li>- HDFC Fixed Deposit</li></ul>		16071.21	81533.88
Guarantee with HDFC Bank) 21550.00 21500.00	(Balancesheld as margin money			
			21550.00	21500 00
		 Total	40679.08	105425.19

			As at March 31, 2022
8. SHORT TERM LOANS AND ADVANCES			
(Unsecured and considered good)			
Advance to Suppliers Advance Recoverable in Cash or in kind or for Value to be received		1107.43 218211.19	31720.48 165880.35
	Total	219318.62	197600.83
9. SHARE CAPITAL			
AUTHORISIED			
6000000 Equity shares of RS.10/- each		600000.0	00 600000.00
		600000.0	00 600000.00
Issued, Subscribed and Fully paid-up			_
5100800 Equity shares of Rs.10/- each, fully paid up		510080	0.00 510080.00
Less:			
Calls in Arrears / unpaid Allotment Money (13,59,500 Equity Shares)		135950	0.00 13595.00
		374130	0.00 374130.00
Add: Share Forfeiture ( Partly Paid up 13,59,500 Equity Shares forfeited)		70985	5.00 70985.00
		445115	5.00 445115.00

	31.03	3.2023	31.03.2022		
Particulars	No. of Shares	Amount (in Rs. Hundres)	No. of Shares	Amount(in Rs. Hundreds)	
Reconciliation of Shares					
Fully Paid up Shares Outstanding At the Beginning of the Year	37,413.00	3,74,130.00	37,413.00	3,74,130.00	
Partly Paid Shares Outstanding At the Beginning of the Year	-	-		-	
Add:					
Shares Issued During the Year	-	-	-	-	
Partly Paid up Shares converted into Fully Paid Up	-	-	-	-	
Calls in Arrears received during the year	-	-	-	-	
<u>Less</u> :					
Shares Bought back during the year	-	-	-	-	
Fully Paid up Shares Outstanding At the End of the Year	37,413.00	374130.00	37,413.00	374130.00	
Partly Paid Shares Outstanding At the End of the Year	-	-	-	-	
Share Forfeited by the Company	13,595.00	70,985.00	13595.00	70,985.00	

# **Equity shares**

Shareholders holding more than 5% shares based on legal ownership in the subscribed share capital of the Company is set out below:

Name of the shareholder	Category As at March 31, 2023 As a		As at March 31, 2023		rch 31, 2022
		No. of Shares	% held	No. of Shares	% held
Alkesh M Gopani	Promoter	670380	17.92%	670380	17.92%
Vipul M. Gopani	Promoter	481370	12.87%	481370	12.87%
Meena Alkesh Gosalia	Non - Promoter	424800	11.35%	170000	4.54%
Pradip R Gosalia	Non - Promoter	250500	6.70%	250000	6.68%
Shah Jyotsana Ramniklal	Non - Promoter	250000	6.68%	250000	6.68%
Pravina Mahashukh Gopani	Promoter	700	0.02%	700	0.02%
Alkesh R Gosalia #	Non - Promoter	0	0.00%	254800	6.81%
Others	Non - Promoter	16,63,550	44.46%	16,64,050	44.48%
Total		3741300	100%	3741300	100%

<sup>#254800 (6.81%)</sup> shares of Alkesh R. Gosalia has been transmitted to Meena Alkesh Gosalia.

#### **10. RESERVES AND SURPLUS**

Opening balance	1 ,50,877.96	1,36,726.64
Add : Profit/(loss) for the year	(104.07)	14,151.33
Closing Balance	1,50,773.90	<u>1,50,877.96</u>
Less: Transferred		

Total 1,50,773.900 1,50,877.96

Sub -

#### 11. LONG-TERM

### **BORROWINGS Secured**

HDFC Bank Loan	2,71,512.01	3,09,027.19
'- Term Loan from HDFC Bank Loan is payable by way of monthly installment of		

513220/- each. The Loans is secured against all the Immovable property situated on the land admn. Sq. Mtr. 15903.91 ie. 19021.54 Sq. Yards of Plot No. 20, Survey No. 52/P Hadamtala Tal. Kotda Sangani, Dist. Rajkot

#### HDFC Bank OD A/c. No. 50200037778512

1151 C 5011K C5 74 C1 11C1 50200007770522			
Loans is secured against all the Immovable proper Mtr. 15903.91 ie. 19021.54 Sq. Yards of Plot No. 2	, · · · · · · · · · · · · · · · · · · ·	83,378.93	0.00
With: 15505:51 ic: 15021:54 5q: raras of Flot No. 2	io, sarvey ivo: sz/r riadamitaia		
Tal. Kotda Sangani, Dist. Rajkot			

### HDFC Bank Loan A/c.

- Loan was sanctioned during FY 2020-21 under the scheme of LAP MORTGAGE GECL 45,387.33 68,024.96 From HDFC Bank Ltd. The loan is repayable by way of monthly installment of

- Rs. 2,31,108/- each along with interest.

# HDFC Bank Ltd - Motor Car Loan A/C

- HDFC Bank Ltd Vehicle Loan (against Hypo.) is repayable in Monthly installment of Rs.
41490 each along withinterest. The loan is secured by hypothecation of KIA Seltos Car of the company.

Total 4,00,278.27 3,81,243.83

-			
From Directors Relatives From Earst-while Director Loans from Corporate Bodies where Common Directors are Interested  STOTAL Long Term Borrowings (Secured & Unsecured) Less: Current maturities of long-term borrowings at the year end (Disclosed Under the Head "Other Current Liabilities"(Note No. 13)  Total The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables For Goods & Services  Up To One Year More than One Year For Expenses For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues levance from Customers  Total  14. SHORT TERM PROVISIONS  rrovision for Taxes buties and Taxes			
From Earst-while Director Loans from Corporate Bodies where Common Directors are Interested  STOTAL Long Term Borrowings (Secured & Unsecured)  Less: Current maturities of long-term borrowings at the year end (Disclosed Under the Head "Other Current Liabilities" (Note No. 13)  Total  The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability  urrent maturities of Long Term Debts atutory dues livence from Customers  Total  14. SHORT TERM PROVISIONS  rovision for Taxes buties and Taxes		-	12000.00
Loans from Corporate Bodies where Common Directors are Interested  S Total Long Term Borrowings (Secured & Unsecured)  Less: Current maturities of long-term borrowings at the year end (Disclosed Under the Head "Other Current Liabilities" (Note No. 13)  Total  The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues twance from Customers  Total  14. SHORT TERM PROVISIONS  rrovision for Taxes buties and Taxes		25000.00	25000.00
Total Long Term Borrowings (Secured & Unsecured)  Less: Current maturities of long-term borrowings at the year end (Disclosed Under the Head "Other Current Liabilities" (Note No. 13)  Total  The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues it ance from Customers  Total  14. SHORT TERM PROVISIONS  rrovision for Taxes buties and Taxes		111950.00	99950.00 -
Total Long Term Borrowings (Secured & Unsecured)  Less: Current maturities of long-term borrowings at the year end (Disclosed Under the Head "Other Current Liabilities" (Note No. 13)  Total  The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability  Internet maturities of Long Term Debts autory dues it was from Customers  Total  14. SHORT TERM PROVISIONS  Trovision for Taxes  Particular Amount of Liability  Total  Total  15. SHORT TERM PROVISIONS	Sub-		
Less: Current maturities of long-term borrowings at the year end (Disclosed Under the Head "Other Current Liabilities"(Note No. 13)  Total  The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables For Goods & Services  Up To One Year More than One Year For Expenses For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues thance from Customers  Total  14. SHORT TERM PROVISIONS rovision for Taxes puties and Taxes	Total	l <u>136950.00</u>	136950.00
(Disclosed Under the Head "Other Current Liabilities" (Note No. 13)  Total  The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability  urrent maturities of Long Term Debts atutory dues than Contact of Long Term Debts atutory dues than Contact of Long Term Total  14. SHORT TERM PROVISIONS  rovision for Taxes buties and Taxes		<u>537228.27</u>	518193.83
Total The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables For Goods & Services  Up To One Year More than One Year For Expenses For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues Ivance from Customers  Total  14. SHORT TERM PROVISIONS Irovision for Taxes Success Included Amount Includes  Total		89319.24	65869.01
The Above Amount Includes  Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables For Goods & Services  Up To One Year More than One Year For Expenses For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues Ivance from Customers  Total  14. SHORT TERM PROVISIONS Trovision for Taxes Success Total			
Secured Borrowings  Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS  rovision for Taxes outles and Taxes	al	447909.03	452324.8
Unsecured Borrowings  Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total			
Total  12. TRADE PAYABLES  Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES  ther Current Liability  urrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS  trovision for Taxes  uties and Taxes		400278.27	381243.8
Trade payables For Goods & Services Up To One Year More than One Year For Expenses For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES Ther Current Liability Irrent maturities of Long Term Debts atutory dues Ivance from Customers  Total  14. SHORT TERM PROVISIONS Irrovision for Taxes Juties and Taxes		136950.00	136950.0
Trade payables  For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability  Interest maturities of Long Term Debts atutory dues divance from Customers  Total  14. SHORT TERM PROVISIONS  Trovision for Taxes  Justies and Taxes	al	537228.27	518193.83
For Goods & Services  Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total			
Up To One Year  More than One Year  For Expenses  For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES  ther Current Liability  urrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS  rovision for Taxes  puties and Taxes			
More than One Year  For Expenses  For Capital Expenditure  Total		1,44,359.83	2,45,308.4
For Expenses For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability arrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS trovision for Taxes  Duties and Taxes		1,46,720.55	2,45,308.4
For Capital Expenditure  Total  13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS trovision for Taxes Outles and Taxes		0.00	0.0
13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS trovision for Taxes  Duties and Taxes		1,09,139.17	81,761.64
13. OTHER CURRENT LIABILITIES ther Current Liability urrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS trovision for Taxes  Duties and Taxes		2,12,920.23	2,25,040.6
ther Current Liability  Irrent maturities of Long Term Debts atutory dues Idvance from Customers  Total  14. SHORT TERM PROVISIONS  Provision for Taxes  Duties and Taxes	_	4,66,419.23	5,52,110.7
ther Current Liability  Irrent maturities of Long Term Debts atutory dues Idvance from Customers  Total  14. SHORT TERM PROVISIONS  Provision for Taxes  Duties and Taxes			
atrent maturities of Long Term Debts atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS Provision for Taxes Outlies and Taxes		57,065.24	4 20,074.5
atutory dues dvance from Customers  Total  14. SHORT TERM PROVISIONS  Provision for Taxes Outlies and Taxes		89,319.24	
Total  14. SHORT TERM PROVISIONS  Provision for Taxes  Outlies and Taxes		0.00	
14. SHORT TERM PROVISIONS Provision for Taxes Outlies and Taxes	_	_ 3,986.3	
rovision for Taxes Outies and Taxes		1,50,370.8	<u>85,943.5</u>
Outies and Taxes			
		18,597.3	3 22,500.0
		26,748.83	•
TONSION FOR EXPENSES		51,525.0	
·	Total		

# Notes forming part of Profit & Loss Account

( Amt. Hundreds)

		For The year ended March 31, 2023	For The year ended March 31, 2022
15. REVENUE FROM OPERATIONS			
Local		11,47,451.62	12,93,457.28
Labour Job Work		3,94,902.88	5,30,943.39
Freight Outward Exp. (Sales) Export		80.00	600.00 11,130
Total		15,42,434.50	18,25,111.98
16. OTHER INCOME			
Bank Interest Income		743.65	1,235.08
Credit card incentives A/c.		32.75	84.34
Credit Written Back A/c		0.00	859.14
Interest on Income Tax Refund A/c.		208.80	0.00
Interest Income on PGVCL Security Deposit		575.90	556.60
Tower Rent Income		2,373.29	2,243.84
Interest Income on MSME Outstanding		37.74	1,299.08
Total		3,972.13	6 ,278.08
17. COST OF MATERIALS CONSUMED			
Opening stock of Raw Material		1,72,805.11	2,40,242.09
Opening of Stock in process		1,07,944.82	1,51,181.89
		2,80,749.93	3,91,423.98
Add: Raw Material Purchase		6,87,318.85	5,56,330.47
Add: Freight Exp.		7,305.28	4,789.52
		9,75,374.06	9,52,543.97
Less: Closing stock of Raw Material		1,14,500.50	1,72,805.11
Less: Closing Stock S.I.P		3,09,510.06	1,07,944.82
		4,24,010.56	2,80,749.93
Total		5,51,363.50	6,71,794.04
18. (INCREASE)/DECREASE IN INVENTORIES			
Closing inventories			
Finished goods		0	0
Stores		6600.00	4500.00
	Sub-Total	6600.00	4500.00

Opening inventories			
Finished goods		0	0
Stores		4500.00	3890.00
	Sub-Total	4500.00	3890.00
Total		(2100.00)	(610.00)
19. EMPLOYEE BENEFITS EXPENSE		2 77 054 65	2 22 700 65
Salary & Wages Other Benefit		2,77,954.65 2,225.00	3,22,700.65 23,460.00
Total		2,80,179.65	3,46,160.65
20. FINANCE COSTS			
Bank Charges & Commission		1,825.14	3,401.89
Motor Car Loan Interest		184.17	596.85
Interest Exp		33,978.07	34,582.46
Interest on Delayed Payment Exp. A/C		23,373.07	0
,, <del></del>		918.02	
Total		36,905.40	38,581.20
21. OTHER EXPENSES			
Manufacturing Expenses			
Consumable Exp.		22,286.56	35,835.11
Canteen Exps.		18,469.30	17,451.90
ETP Maintenance Exp.		15,562.45	17,734.79
Electricity Exps.		1,01,584.88	1,12,524.94
Fuel Expenses		91,899.51	1,12,830.66
Hydrogenation Job work Charges		22,692.08	16,010.88
Boiler Repairs & Replacement Exps.		973.00	941.70
Plant Repairs & Maintenance Exps.		30,379.65	34,737.53
Safety Equipment Exp.		995.10	1,476.80
Local Transportation & Rickshaw Fare Exp.		3,600.80	4,588.95
Sample Testing Charges		18,916.50	20,181.35
Sundry Factory Exps.		6,754.92	7,881.64
		3,34,114.74	3,82,196.24
Administration & Selling Exps.			
Advertisement Expense		1,814.80	663.82
Audit Fees		1,350.00	1,000.00
Air Conditioner Repairs and maintenance		963.90	366.06
Bad Debts A/c.		-	507.50
Books & Periodicals Exp.		18.00	18.00
Building Repairs and maintenance		5,688.90	7,505.26
Computer Repairs & Maintenance Exp		894.97	1,063.59

Charity & Donation Exp.	188.00	690.50
Co. Professional Tax Exp.	24.00	24.00
Credit card charges A/c.	51.65	130.81
Discount & Remission	(0.27)	(93.56)
Electric Maintenance Exps.	4,538.16	5,507.95
Freight outward Exp	3,886.32	8,497.72
Food & Beverages Exps.	1,732.85	339.16
Foreign Exchange Rate Difference (Loss)	-	273.74
Travelling Expense (Others)	1,728.37	2,435.34
Director Travelling Expense ( Domestic - Foreign)	2,102.86	334.69
Furniture & Fixtures Repairing Exps.	-	346.75
Garden Exps.	365.50	188.50
GST Tax Expenses	2,280.69	835.21
GST Interest A/c.	351.11	240.88
Hotel Accommodation Exp.	548.35	451.42
Insurance Exp	7,447.78	5,490.63
Income Tax Interest A/c.	2,742.56	78.00
Land Revenue Exp.	-	167.00
Legal Fees Exp.	-	1,115.33
Professional Fees Exp.	28,493.73	35,870.41
License Application/ Renewal Fees A/c	734.40	1,623.49
Laboratory Repairing Exps.	4,650.49	5,689.09
Loading & Forwarding	327.50	0
Membership & Subscription Exps.	716.73	100.00
Motor Car Fuel Exp.	5,757.38	5,651.10
Motor Car Insu. Premium A/c.	1,300.76	1,368.83
Motor Car Repairing Exps.	1,415.11	5,543.99
Manpower Service Charge	344.92	355.90
Postage & Courier Exp	1,870.77	1,171.39
Packaging and Forwarding Expenses	7,337.01	8,514.83
Pre-Operative Exp. Written Off	39,614.00	39,614.00
Professional Training, Coaching & Development Exp.	290.00	235.99
Stationary Printing & Xerox Exp	1,706.16	2,435.19
Tea-Coffee Exp	4,730.83	4,961.09
Telephone Exp	1,394.03	1,454.81
Telephone Repairing Exp.	35.20	16.90
Statutory Analytical Charges	195.47	279.18
Security Expense	1,302.14	2,841.50
Staff Medical Exps./ Excess Claim received	(288.72)	4,958.75

Staff Welfare Expense	-	100.80
Provident Fund Expenses	1,442.16	362.04
Stock Exchange Fees	3,000.00	3,000.00
Process Trouble shooting Charge	6,456.90	4,250.00
Sundry Expenses	-	151.69
Sundry Repairs Exp.	119.00	31.00
Weigh Scale Exp.	235.75	171.75
Round Off	(0.01)	0.00
	81,278.44	1,69,732.00

#### 22. SIGNIFICANT ACCOUNTING POLICIES:

#### 1. IND AS 1 PRESENTATION OF FINANCIAL STATEMENTS:

IND AS 1 PRESENTATION OF FINANCIAL STATEMENTS: These financial statements have been prepared under historical cost convention from books of accounts maintained on an accrual basis (unless otherwise stated hereinafter) in conformity with accounting principles generally accepted in India and comply with the Accounting Standards issued by the Institute of Chartered Accountants of India and referred to Section 133 read with Rule 7 of the Companies (Accounts) rules, 2014 except as required by IND AS 19 - Employee benefits. The accounting policies applied by the company are consistent with those used in previous year.

The preparation of financial statements in conformity with GAAP requires that the management of the company makes estimates and assumptions that affect the reported amounts of income and expenses of the period, the reported balances of assets and liabilities and the disclosure relating to contingent liabilities as of the date of the financial statements.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle as arrived at by management, and other criteria set out in the revised Schedule III Division II to the Companies Act, 2013, based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The comparative figures in the Balance Sheet as at March 31, 2023 and March 31, 2023 and Statement of profit and loss and Cash Flow Statement for the year ended March 31, 2023 have been restated accordingly. Accounting Policies have been consistently applied except where newly issued accounting standards is initially adopted or revision to existing standards required a change in the accounting policy thereto in use. Management evaluates all recently issued or revised accounting standards on and on-going basis.

#### 2. IND AS 16 PROPERTY, PLANT and EQUIPMENT:

Fixed Assets are stated at historical cost less accumulated depreciation and impairment losses, such cost being exclusive of excise duty/GST. The cost of an asset comprises its purchase price and directly attributable cost of bringing the assets to working condition for its intended use. Expenditure for additions and improvements are capitalized as and when incurred.

#### DEPRECIATION:

Depreciation for the year on all assets is provided for on written down value method. (i) On carrying amount of fixed Asset brought forward from earlier year, at the rates derived from estimates of useful lives made by management as mentioned in following table, (ii) on Fixed assets added during the year, at the rates derived from useful lives stated in schedule II to Companies Act, 2013.

Sr. No.	Major Head	Asset Included	Useful life
1	Building	Building	30 years
2	Plant and Machinery	All Plant and Machinery	15 years
3	Furniture and Fixtures	All Furniture and Fixtures	10 years
4	Office Equipment	All office Equipment	5 years
5	Vehicles	All Motor car	10 years
6	Computer and data processing units	All Computer related Items	6 years

#### 3. FINANCIAL LIABILITIES:

Initial Recognition and Measurement:

Financial Liabilities are initially recognized at fair value plus any transaction costs, (if any) which are attributable to acquisition of the financial liabilities.

#### 4. CURRENT/ NON CURRENT CLASSIFICATION:

An asset is classified as current if:

- (a) It is expected to be realized or sold or consumed in the Company's normal operating cycle;
- (b) It is held primarily for the purpose of trading;
- (c) It is expected to be realized within twelve months after the reporting period; or
- (d) It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability classified as current if:

- (a) It is expected to be settled in normal operating cycle;
- (b) It is held primarily for the purpose of trading
- (c) It is expected to be settled within twelve months after the reporting period
- (d) it has no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

#### 5. SHARE CAPITAL:

Ordinary Shares are classified as equity. Incremental costs directly attributable to the issue of new Ordinary shares or share options are recognized as a deduction from equity, net of any tax effects.

### 6. INVESTMENTS:

The Company hold no investment.

Long term Investments are stated at cost. Provision for diminution in the value if long term investment is made only when such decline is not temporary

#### 7. IND AS 18 REVENUE:

Revenue is recognized only when it is probable that the economic benefits associated with the transaction will flow to the entity. Sales are exclusively of VAT, Excise Duty and Service Tax and GST.

#### 8. PURCHASE:

Purchase of Raw Material where Cenvat credit and VAT credit and GST Credit is available are exclusive of Excise duty and VAT, GST

#### 9. IND AS 2 INVENTORIES:

The cost of inventories shall comprise all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. Inventories should have been Valued as below:

Raw Material & Stores: Lower of Cost or Net Realizable Value Semi

Finished Goods/WIP Stock: At RM Cost + Conversion CostFinished Goods:

Lower of Cost or Net Realizable Value

Company has maintained WIP stock records at Raw Material Cost however Conversion Cost as per Ind AS-2 Inventories has not been maintained/made available by company to verify and quantify VALUE OF W I P Stocks and its impact on true and correctness of Financial Statements prepared in accordance with Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

#### 10. IND AS 12 INCOME TAX:

Current year tax is provided based on the taxable income computed in accordance with the Income Tax Act 1961

Deferred Tax is recognized, subject to consideration of prudence, on timing differences, representing the difference between the taxable income/loss and accounting income/loss that originated in one period and are capable of reversal in one or more subsequent periods. Deferred Tax assets and liabilities are measured using tax rules and tax laws that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets Viz. unabsorbed depreciation and carry forward losses are recognized if there is virtual certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

In accordance with IND AS 12, "Income Tax ", issued by The Institute of Chartered Accountants of India, the company has recognized deferred tax liabilities for the current year. The company has started generating cash profits and based on the future projections, the management is certain that the company shall be able to avail set-off of the carried forward losses against taxable profits.

(Amt. in Rs. hundreds)

Deferred Tax Liability as on 01.04.2022	17,736	23,089
Add:		
Provision for Deferred tax Asset during the financial year on account of depreciation	3,629	5,353
Deferred Tax Liability as on 31.03.2023	14,107	17,736

### 11. IND AS 19 EMPLOYMENT BENEFITS:

Employees Benefits are accounted on cash basis.

Though Accounting Standard IND AS 19 issued by the Institute of Chartered Accountants of India is mandatory, the firm has not made Provision for Leave Encashment Benefit and payment of gratuity on retirement of employee as the quantum of liability is not ascertainable due to the availability of leave encashment benefit and availment of leave any time during the service period. There were no share based payments made to any of the employees.

#### 12. IND AS 24 RELATED PARTY DISCLOSURES:

(I) Key Management Personnel

Mr. Umang Alkesh Gosalia

Mr. Pramay Chhatra (Ceased to be Director from 25.04.2023)

Ms. Ami Rajeshbhai Shah

Mr. Yash Vora

Mr. Keyur Vora

Mr. Nikhil Uchat (Appointed as Director w.e.f 25.04.2023)

(II) Enterprises owned or significantly influenced by Key Management personnel or their relatives

M/s Malwin Pharma Pvt Ltd - Mr. Umang Alkesh Gosalia is common Director

(Amt. in Hundreds.)

Sr. No.	Name of Person / Entity	Relation	Nature of Transaction	Amount Involved
1.	Umang A. Gosalia	Managing Director	Director Salary	39,000.00
2.	Namrata U. Gosalia	Relative of Managing Director	Employee Salary	9,000.00
3.	Meena A. Gosalia	Relative of Managing Director	Employee Salary	12,000.00
4.	Malwin Pharma Pvt Ltd	Umang Gosalia is Common Director	Inter corporate loan repayment	28.10

#### 13. IND AS 108 OPERATING SEGMENT:

The company has only one principal place of business and operates in only one type of business hence segment reporting isnot made.

14. IND AS 20 ACCOUNTING FOR GOVERNMENT GRANTS AND DISCLOSURE OF GOVERNMENT ASSISTANCE : The Govt. Grants subsidies or export incentives received by the company are properly accounted.

#### 15. IND AS 23 BORROWING COST:

Borrowing costs that are attributable to acquisition or construction of qualified as part of the cost such assets. A Qualifies asset is one that takes substantial period of time to get ready for intended use. All other borrowing costs are charged to revenue.

# 16. IND AS 17 LEASES:

The company has not entered in to any lease transaction during the financial year, hence the clause is not applicable.

#### 17. IND AS 36 IMPAIRMENT OF ASSETS:

The carrying values of assets/cash generating units at each Balance Sheet date are reviewed for impairment. If any indication of impairment exists, the recoverable amount of such assets is estimated and impairment is recognized, if the carrying amount of these assets exceeds their recoverable amount. The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor. When there is indication that an impairment loss recognised for an asset in earlier accounting periods no longer exists or may have decreased such reversal of impairment loss is recognized in the Statement of Profit and Loss, except in case of revalued assets.

In opinion of management, there are no indication of impairment of assets as on 31.03.2023 so no effect of impairment is required to be given in books of accounts

#### 18. IND AS 37 PROVISIONS CONTINGENT LIABILITIES AND CONTINGENT ASSETS:

Provision is recognized when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates.

#### 19. IND AS 8 ACCOUNTING POLICIES, CHANGES IN ACCOUNTING ESTIMATES AND ERRORS:

The preparation of financial statements requires, estimates and assumptions to be made that affect the application of accounting policies and the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed at each Balance Sheet date. Revisions in the estimates are recognized in the periods in which the results are known/materialize.

#### 20. IND AS 33 EARNINGS PER SHARE (EPS):

(Amt. in Rs.)

Particulars	As at March 31,2023	As at March 31,2022
Basic/ weighted average number of equity shares		
outstanding during the year	3,741,300	3,741,300
Profit/(loss) for the year	-10,40,434	1,415,232
Nominal value of equity share (Rs.)	10	10
Basic and diluted EPS (Rs.)	-0.28	0.38

#### 21. IND AS 21 EFFECTS OF CHANGES IN FOREIGN EXCHANGE RATES:

Foreign currency transactions are accounted for at the rates prevailing on the date of transaction. Difference arising out of foreign exchange rates is dealt with in the Profit & Loss account. Current assets and current liabilities relating to foreign currency transactions remaining unsettled at the end of the year are translated at the closing rates and profit or loss arising there from, if any, is dealt with in the Profit & Loss account.

#### 22. MANAGEMENT REMUNERATION:

Disclosures with respect to the remuneration of directors and employees as required under section 197 of Companies Act, 2013 and Rule 5(1) Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 has been provided in the following table:

(Amt. in Rs. Hundreds)

Sr. No.	Particulars of remuneration	Name of the Managerial Person MD/ WTD/ Manager	Name of the Managerial Person other than MD/ WTD/Manager		Total Amount
		Umang Gosaliaas Managing Director#	Keyur Vora as CFO	Yash Vora as CS	
1	Gross Salary	39,000.00	13,886.40	5,854.20	58,740.60
	a) Salary as per provisions contained in section 17(1) of Income tax Act , 1961	-	-	-	-
	b) Value of Perquisites u/s 17(2) of Income Tax Act , 1961	-	-	-	-
	c) Profits in lieu of salary under section 17(3) Income Tax Act, 1961	-	1	-	-
2	Stock Option	-	ı	-	-
3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
5	Any Other Benefits (Gratuity )	-	-	-	-
	Total	39,000.00	13,886.40	5,854.20	58,740.60

# 23. Payment to Auditors:

(Amt. in Rs. Hundreds)

Auditors Remuneration	2022-2023	2021-2022
Audit Fees	1,350.00	1,000.00
Tax Audit Fees	0	0
Company Law Matters	0	0
GST	0	0
Total	1,350.00	1,000.00

### 24. MISCELLANEOUS EXPENDITURE:

In the current year, company have incurred Product Development Expenses for research and development of a product which is classified under Miscellaneous expenditure under non-current assets. Company have not charged any such miscellaneous Expenditure in the Profit and loss account of during the year.

29<sup>th</sup> Annual Report Parmax Pharma Limited

#### 25. Contingent Liabilities & Commitments:

(Amt. in Rs. Hundreds)

Particulars	2022-2023	2021-2022
(i) Contingent Liabilities		
(a) Bank Guarantees issued by bank on behalf of Company for which company has issued counter guarantee	1,00,000.00	1,00,000.00
(ii) Commitments		
(a) Estimated amount of Contracts to be executed on capital account and not provided for	-	-

#### 23. OTHER EXPLANATORY NOTES:

- i. The Company has not received any memorandum (as required to be filed by the suppliers with the notified authority under the Micro, Small and Medium Enterprises Development Act, 2006) claiming their status as on 31st March, 2023 as micro, small or medium enterprises. Consequently the amount paid/payable to these parties could not be ascertained. Hence no provision has been made in the books of accounts.
- ii. Balance with Parties are subject to reconciliation / confirmation with / by them. In absence of such confirmations, balances are as per books are taken and relied upon by the auditors.
- iii. Payments received / made through third parties are subject to confirmation.
- iv. Wherever any supporting are not made available in respect of any expenses / entries, the same is relied upon the information's and explanations given by the management to the auditors.
- v. Fixed Assets are stated as certified by the Management of the company. The Auditors neither verify the same nor were any details as to physical verification of the same made available to the Auditors
- vi. Previous Year's figure has been re-grouped/re-arranged wherever necessary.

#### 24. Other Disclosures:

(A) Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006:

The company is in the process of obtaining information regarding enterprises covered under Micro, Small and Medium Enterprises as per MSMED Act, 2006. However no information from any enterprise regarding above has been received by the company, and therefore no information is available with the company. The Company has not made any payment of Interest nor provided Interest payable if any on dues to suppliers.

For B A Shah S R Mehta & Co.

**Chartered Accountants** 

Firm Registration No.: 128796W

For Parmax Pharma Limited

Dr. Umang Gosalia **Managing Director** 

Nikhil Uchat Director

DIN: 05153830

DIN: 08427983

Malay Shah Partner

Membership No. 159526

UDIN: 23159526BGYPIN1016

Date : 30.05.2023 Place : Rajkot

Keyur Vora

Yash Vora **Company Secretary** 


CFO

: 30.05.2023

Date Place : Rajkot

# **Key Financial Ratios**

Ratio	Numerator	Denominator	C.Y. Ratio	P.Y. Ratio	% Change	Reason for variance (In case of Variation more than 25%)
(a) Current Ratio	Current Assets	Current Liabilities	1.05	0.90	17.63%	NA
(b) Debt-Equity Ratio	Long Term Debt + Short Term Debt	Shareholder equity	0.92	0.87	5.52%	NA
(c) Debt Service Coverage Ratio	Earnings Before Interest, tax, Depreciation & Amortization	Total principal + Interest on Borrowings	2.77	3.29	-15.81%	NA
(d) Return on Equity Ratio	Earning After Interest, tax, Depreciation & Amortization	Average Shareholder's Equity	0.38	0.39	-1.31%	NA
(e) Inventory turnover ratio	Turnover	Average Inventory	4.50	2.65	70.18%	Inventory Turnover Ratio improved due to quick conversion and sale of goods and it depends on the Business model.
(f)Trade Receivables turnover ratio	Net Credit Sales	Average Trade Receivable	0.48	0.45	8.86%	NA
(g) Trade payables turnover ratio	Net Credit Purchase	Average Trade Payable	2.52	5.29	-52.37%	This ratio has been impacted due to varied agreed credit terms with the vendors and suppliers
(h) Net capital turnover ratio	Total Sales	Average Working Capital	-39.33	24.19	-262.58%	This ratio has been impacted due to decrease in revenue & Profit of Company during the financial year
(i) Net profit ratio	Net Profit	Net Sales	0.00	0.02	-82.0%	This ratio has been impacted due to decrease in revenue & Profit of Company during the financial year.
(j) Return on Capital employed	Earnings Before Interest & tax	Capital employed	0.07	0.12	-38.68%	This ratio has been impacted due to decrease in revenue & Profit of Company during the financial year





Parmax Pharma Limited
Registered Office:
Plot No. 20, Survey No. 52,
Rajkot-Gondal National Highway No. 27,
Hadamtala, Tal. Kotda Sangani,
Rajkot - 360311, Gujarat
Contact Number: 02827 – 270 534 /35/36

Email: - info@parmaxpharma.com